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SUMMARY
The c-JunN-terminal kinases (JNKs), asmembers of themitogen-
activated protein kinase (MAPK) family, mediate eukaryotic cell
responses to a wide range of abiotic and biotic stress insults. JNKs
also regulate important physiological processes, including neu-
ronal functions, immunological actions, and embryonic devel-
opment, via their impact on gene expression, cytoskeletal pro-
tein dynamics, and cell death/survival pathways. Although the
JNK pathway has been under study for20 years, its complex-
ity is still perplexing, with multiple protein partners of JNKs
underlying the diversity of actions. Here we review the current
knowledge of JNK structure and isoforms as well as the part-
nerships of JNKs with a range of intracellular proteins. Many of
these proteins are direct substrates of the JNKs. We analyzed
almost 100 of these target proteins in detail within a framework
of their classification based on their regulation by JNKs. Exam-
ples of these JNK substrates include a diverse assortment of
nuclear transcription factors (Jun, ATF2, Myc, Elk1), cytoplas-
mic proteins involved in cytoskeleton regulation (DCX, Tau,
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WDR62) or vesicular transport (JIP1, JIP3), cell membrane
receptors (BMPR2), and mitochondrial proteins (Mcl1, Bim).
In addition, because upstream signaling components impact
JNK activity, we critically assessed the involvement of signaling
scaffolds and the roles of feedback mechanisms in the JNK
pathway. Despite a clarification of many regulatory events in
JNK-dependent signaling during the past decade, many other
structural and mechanistic insights are just beginning to be
revealed. These advances open new opportunities to under-
stand the role of JNK signaling in diverse physiological and
pathophysiological states.
INTRODUCTION
Protein kinases are intracellular signaling enzymes that catalyzethe phosphorylation of specific residues in their target sub-
strate proteins. Despite a basic appreciation of the regulatory roles
played by protein phosphorylation across a broad range of aspects
of biology, many questions remain outstanding. Little is known
about how phosphorylation directlymodifies protein function. In
many cases, it is not known how these molecular changes then
influence the activity of signaling intermediates to impact ulti-
mately on cellular behavior or how thesemechanistic insights into
phospho-protein function could be integrated with cellular-level
observations to improve our understanding of both health and
disease.
In this review, we survey the current understanding of the c-
Jun N-terminal kinase (JNK) subfamily of Ser/Thr protein ki-
nases. Signaling by the JNKs has been intensely studied for more
than 2 decades, with several previous reviews covering general
aspects (1) or some covering more specific aspects, such as JNK
signaling in the brain or the opportunities for inhibition of JNK
signaling as a therapeutic strategy in cancer (2, 3). Indeed, JNKs
have attracted attention as potential pharmaceutical targets
through their implication via biochemical, cellular, and systems-
level approaches in disease development (4, 5). Although this re-
view is broad in scope, its foundations lie in an exploration of the
current molecular and mechanistic understanding of JNK-medi-
ated signaling pathways, including a critical appraisal of how core
JNK signalingmodules assemble, the diversity of the JNK proteins
themselves, and how JNKs connect with partner proteins.
We then assess the functional consequences of JNK-mediated
phosphorylation on known substrate proteins. Indeed, the num-
ber of known and well-validated JNK substrates is now close to
100. This has prompted our mechanistic classification of the role
of JNK-mediated phosphorylation among these functionally di-
verse substrate proteins; the intense research in the field before
and after our former review, published in 2006 in Microbiology
and Molecular Biology Reviews (1), provided our framework. Im-
portantly, the functional diversity of JNK substrates readily ex-
plains why JNK signaling is so pervasive and how it controls such
diverse processes. In our final section, we discuss how the critical
roles for JNK signaling in mammals help to explain whymicrobes
often “tinker” with JNK signaling pathways to use them to their
own advantage. Although knowledge remains rudimentary for
many of these aspects, a molecular-level understanding of JNK
enzyme-substrate partnerships holds the promise, in combination
with the results of emerging systems-level studies, to ultimately
lead to a more complete understanding of JNK signaling.
CONTROL OF ACTIVITY AND LOCALIZATION OF JNK
PATHWAYS
The Molecular Architecture of Core JNK Pathways
Protein kinases, such as JNKs of the mitogen-activated protein
kinase (MAPK) family, relay, amplify, and integrate signals from a
diverse range of intra- and extracellular stimuli. All MAPKs are
Ser/Thr kinases that belong to the so-called CMGC kinase group
(named after its best-known members: cyclin-dependent kinases
[CDKs], MAPKs, glycogen synthase kinase 3 [GSK3], and CDK-
like kinases [CLKs]). The CMGC kinases share many similarities
within their kinase domains, especially in the vicinity of their cat-
alytic site; as a result, they recognize identical or very similar con-
sensus sequences in their targeted substrate proteins. Apart from
some constitutively active members, most CMGC kinases (and all
MAPKs) require phosphorylation of their activation loop for full
catalytic activity. In the case of classical MAPKs, such as the JNKs,
extracellular signal-regulated kinases 1/2 (ERK1/2), p38, or ERK5,
two phosphorylation events within a typical Thr-x-Tyr motif
(TxY in general, TPY in the case of JNKs) within the activation
loop are required. The Ste7 family of kinases, better known as
MAPK kinases or MAP2Ks, catalyze these phosphorylation
events, whereas several phosphatases catalyze the removal of ei-
ther or both phosphate groups to inactivate these kinases. Thus,
there is direct control of the activities of the MAPKs, such as the
JNKs, by the coordinated actions of positive and negative regula-
tors.
More broadly, JNKs are components of canonical signal trans-
duction cascades/pathways described generically as the “three-
tiered”MAPKpathways (Fig. 1).Within these pathways, a top tier
of kinases (MAP3Ks) receives a variety of inputs, a middle tier of
kinases (MAP2Ks) is strictly dependent on the upper tier kinases
for activation, and a lower tier of kinases (MAPKs) phosphoryl-
ates a large number of substrates to elicit regulatory responses;
thus, these MAPKs are considered the effectors of the pathway.
Such multitiered kinase pathways are common in regulatory sys-
tems; other prominent examples include theHippo/LATS and the
AMP-activated protein kinase pathways (6, 7). Furthermore, the
sharing of multiple MAP3Ks and MAP2K between MAPK path-
ways can facilitate pathway cross talk and signal integration, thus
providing a coordinated response to each activating signal.
JNK pathways are activated in response to a wide range of stim-
uli but most notably following cell exposure to a variety of biotic
or abiotic stress events, such as infection, inflammation, oxidative
stress, DNA damage, osmotic stress, or cytoskeletal changes, with
the best-characterized pathways being activated downstream of
receptors, including G-protein coupled receptors (GPCRs), Wnt
receptors, transforming growth factor- (TGF-) receptors, tu-
mor necrosis factor (TNF) receptors, and the Toll receptor com-
plex (Fig. 1). In addition, JNK activation has been reported in the
response to endoplasmic reticulum stress (ER stress), downstream
of activation of the ER-resident stress sensor kinase inositol-re-
quiring enzyme 1 (IRE1) (8; see also reference 9 for a review of this
topic). However, there have been subsequent studies indicating
that the autocrine release of the inflammatory cytokine TNF may
mediate these ER stress-activated events (10, 11), akin to initial
suggestions that clustering of cytokine receptors could underlie
JNK activation in response to UV light or osmotic stress (12).
Consistent with the wide range of inputs, the MAP3Ks of the
top MAPK pathway tier are highly variable and do not even form
Zeke et al.
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a single kinase family when their kinase domains are considered:
the MAP3Ks include both Ste20/Ste11/Ste7 (STE) family kinases
(MEKKs, ASK1/2, TAOs) andmembers of the tyrosine kinase-like
(TKL) family (MLKs, DLK, LZK, MTK, TAK1). The additional
diversity of domains outside their kinase domains also likely re-
flects different modes of MAP3K activation. The MAP3Ks of the
JNK pathway include TAK1 (in complex with Tab1 and Tab2/3,
capable of sensing Lys63-linked polyubiquitinylation events at the
TNF receptor and TAK1 itself being regulated by ubiquitination)
(13–18), MEKK1 (through a mechanism involving Lys63-linked
polyubiquitinylation of the Tab1 adaptor protein or other path-
way regulators, including the T-cell receptor [TCR]-associated
scaffold Carma 1) (19–22), MEKK4 (sensing GADD45 proteins,
induced by DNA damage, or acting downstream of TRAF4) (23,
24), ASK1 (regulated by thioredoxin binding, and thus redox sen-
sitive) (25, 26), andMLKs (regulated byGTP-bound small G-pro-
teins of the Rho family, involved in cytoskeletal rearrangement)
(27). Other MAP3Ks have also been described (e.g., MEKK2,
MEKK3, TAO1, and TAO2) that primarily regulate the p38 and
ERK5 MAPK pathways as well as the Hippo/LATS pathway but
which may also have some role in JNK activation (28, 29). This
shared use of kinases again emphasizes the possibilities for path-
way cross talk and signal integration.
The MAP3Ks have been considered the “gatekeepers” of the
MAPK pathways, but despite their importance, most MAP3Ks
remain poorly characterized at a molecular level and no full-
length structures ofMAP3Ks have been determined to date.What
is clear is that the MAP3Ks are tightly controlled by multiple
mechanisms so that they normally cannot be activated in a single
step. Indeed, the activation cycle of most MAP3Ks shows some
similarity to that of receptor tyrosine kinases: many MAP3Ks are
subject to autoinhibition (e.g., MEKK1, MEKK4, MLK3) by var-
ious regulatory domains associating with their kinase domains
(23, 30, 31). Following the relief of autoinhibition (e.g., by protein
ligands), MAP3Ks such as MLK3 or MEKK1 are allosterically ac-
tivated due to kinase domain dimerization (30, 31). For MEKK2,
dimerization of its kinase domain is required for full JNK activa-
tion in cells (32). However, it is still unclear how, at a molecular
level, the catalytically competent kinase domain dimers of these
MAP3Ks form. In the only well-explored example, observations
FIG 1 Overall organization of JNK signaling pathways. JNK pathways are activated by a variety of extracellular stimuli (e.g., cytokines, pathogens, morphogenic
factors, hormones) as well as intracellular stimuli (e.g., oxidative stress, DNA damage), converging on the three JNKs. These phosphorylate a variety of
cytoplasmic as well as nuclear substrates and engage in direct (e.g., phosphorylation of MAP3Ks) as well as indirect (e.g., expression of the dual-specificity
phosphatases MKP1 and MKP5) feedback circuits. The protein kinase members of the core MAPK pathway are displayed in red, while critical proteins directly
controlling MAP3K activation are shown in green. Proteins further upstream of the pathway are colored turquoise, MKPs are blue, and substrates are yellow.
Note that, for the purposes of clarity, not all the known proteins or possible pathways are shown here. Continuous arrows imply direct binding or direct
enzymatic reactions, while dotted arrows show either indirect, multistep reactions or connections where the exact mechanism(s) is uncertain. Abbreviations
(other than the protein names defined in the main text): GPCR, G-protein-coupled receptor; Ubi, ubiquitin (usually nondegradative, with Lys63 linkage).
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for B-Raf from the ERK MAPK cascade suggest its symmetric
dimerization leaves its kinase domains free to accept substrates
(33–35). This is consistent with the dimerization mode observed
for the isolated kinase domains of the MAP3K ASK1 (36). How-
ever, the existence of other modes cannot be excluded, e.g., MLKs
primarily dimerize through coiled-coil interactions (37). Other
noncatalytic proteins can also aid in MAP3K dimerization; one
notable example is the Tab1-Tab2/3 complex, which is indispens-
able for TAK1 activity (15). In some cases, as exemplified byASK2,
the MAP3Ks themselves may lose their catalytic activity and be-
come obligate dimerization partners that enhance the activation
of other related MAP3Ks (38, 39). MAP3K full activation also
requires activation loop autophosphorylation, presumably in
trans, through a transient tetrameric complex (similar to the IB
kinases [IKKs]) (40, 41). This phosphorylation of MAP3Ks in-
creases and stabilizes their activity, removing the requirement of a
dimeric state for substrate phosphorylation. Other auxiliary ki-
nases, generically classified as MAP4Ks, may mediate these and
othermodifications ofMAP3Ks. The inactivation ofMAP3Ks can
also involve feedback phosphorylation events (42–44), the associ-
ation with and phosphorylation by other kinases as reported for
MEKK4 (45), or ubiquitin-directed degradation as reported for
DLK1 (46, 47). Ultimately, following stimulation, phosphatases
can remove the activating phosphate groups, as observed for the
negative regulation of ASK1 by phosphatases, including PP5,
PPM1L (also known previously as PP2C), Cdc25A and Cdc25C
(48–51), or the actions of PP2A or PP6 on TAK1 (52, 53), to allow
the kinases to return to a monomeric, autoinhibited basal state.
The most important MAP3K substrates within the JNK path-
way are the MAP2Ks known as MKK4 and MKK7 (Fig. 1).
MAP2Ks are highly specialized proteins of the STE kinase family,
and MAP3K-mediated phosphorylation is the only reported acti-
vation mechanism for MKK4 or MKK7 under physiological con-
ditions. Most MAP3Ks involved in the JNK pathway can phos-
phorylatemultipleMAP2Ks, including those belonging to the p38
pathway (MKK3 and/orMKK6).Despite suggestions that a “DVD
motif” (whichwas subsequently shown to be a structured segment
of the MAP2K kinase domain critical for domain integrity) (54–
56) would direct MAP3K-MAP2K specificity (57), the issue of
MAP3K substrate selectivity is still largely unresolved. However,
for the DLK-MKK7 complex, the MAP2K-MAP3K interaction
has been mapped: the coiled-coil region of DLK binds to the N-
terminal disordered segment of MKK7 preceding the kinase do-
main (58). Depending on the set of MAP3Ks activated, the degree
of MKK4/MKK7 phosphorylation also varies with the nature of
the pathway-initiating stimulus. For example, interleukin-1 or
TNF- exposure preferentially activated MKK7, whereas MKK4
and MKK7 were both activated following stress; these differences
are in agreement with the failure of cytokines to activate JNKs in
cells isolated from MKK7/ mice, whereas JNK activation fol-
lowing exposure to stress was prevented only in MKK4/
MKK7/ cells (59).
MAP2Ks display very little activity on generic substrates such as
synthetic peptide arrays; their activity appears restricted to the
activation loops of intact kinase domains of their targetedMAPKs.
MKK4 and MKK7 are capable of phosphorylating and activating
JNKs in vitro (60). Under physiological conditions, the two ki-
nases are synergistic in generating double-phosphorylated JNKs
(61). Unlike MKK7, which targets JNKs only, MKK4 can also
phosphorylate p38 both in vitro and in vivo (reviewed in refer-
ence 62). Hence, the JNK and p38 pathways are not truly separate,
even at this middle tier of kinases.
Phosphatases and Feedback Mechanisms in Control of
JNK Activity
By their dephosphorylation of kinases acting within the different
MAPK pathway tiers, protein phosphatases can exert control over
themagnitude and timing ofMAPK activation. For the JNK path-
way, Ser/Thr phosphatases may act as negative regulators, but
little is known about those phosphatases specifically targeting the
upper tiers of MAP3K or MAP2K enzymes. The PP5 and PP2A-
type phosphatases, known as ERKMAPK pathway regulators, are
potential candidates for this role (48, 53, 63–68). For JNKs them-
selves, dual Thr and Tyr phosphorylation within the JNK activa-
tion loop TPY motif is required for full JNK activity; thus, the
removal of either phosphate can decrease JNK activity toward all
substrates. Indeed, Ser/Thr phosphatases can directly regulate
JNK actions. For example, the protein Ser/Thr metallophospha-
tase PPM1J (PP2C) was found to harbor a JNK-binding motif
(69). Since this recruitment or dockingmotif was also found in the
related PPM1H phosphatase and is broadly conserved across the
animal kingdom, these phosphatases may have important roles in
the regulation of JNK pathways. Conversely, MAPK-mediated
phosphorylation of regulatory phosphatases is also known (70,
71), and this phosphorylation has the potential to provide impor-
tant additional control of pathway activation. Thus, specific Ser/
Thr phosphatases have the potential to regulate JNK signaling by
their actions at multiple tiers of the pathway.
Greater attention has been directed toward the contributions of
the dual-specificity phosphatases (DUSPs) that can dephosphor-
ylate both phosphotyrosine and phosphoserine/threonine resi-
dues within their substrate proteins. DUSPs are a large and diverse
family, but a subset specific for MAPK dephosphorylation are
known as MAPK phosphatase (MKPs). The two subfamilies of
MKPs targeting JNK can be distinguished as either inducible, pri-
marily nuclear DUSPs (MKP1/DUSP1 and MKP2/DUSP4) or
predominantly cytoplasmic DUSPs (MKP5/DUSP10, MKP7/
DUSP16, andM3/6 or DUSP8). Notably, MKP1/ or MKP5/
mice display JNK hyperactivation in diverse tissues, supporting
these phosphatases as regulators of low basal JNK enzymatic ac-
tivities (72–75). However, most DUSPs may dephosphorylate
more than a single substrate, e.g., MKP1 and MKP2 target
ERK1/2, p38 kinases, and JNKs (72), whereas MKP5 and MKP7
act on p38 and JNKs (76, 77). In addition to the dual-specificity
phosphatase domain, these phosphatases carry a special noncata-
lytic domain termed the rhodanese domain, due to its structural
similarity to bacterial rhodanese enzymes (78). The role of the
rhodanese domains in MKP1 and MKP5 in recruiting ERK2 and
p38 is well-known: by mimicking a so-called docking motif, this
surface enables strong interactions with several MAPKs (79).
However, the docking site of JNK cannot bind rhodanese do-
mains, so phosphatases targeting JNKbind in alternativeways (via
their catalytic domain or by docking motifs, as observed inMKP5
and MKP7 [80, 81]). In vivo studies suggest that MKP1 is not
required for growth factor signaling; however, it is essential for
immune cell activation, as MKP1/ mice show immune defects
(82). Similar phenotypes were observed for MKP5/ mice (75).
In addition, MKP1 controls JNK activity that is critical for appro-
priate axon branching in developing cortical neurons (83) as well
as apoptosis of sympathetic neurons due to nerve growth factor
Zeke et al.
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withdrawal (84). Such findings emphasize the importance of these
MAPK-directed DUSPs.
As the MKPs that dephosphorylate JNKs can also dephosphor-
ylate p38, the regulatory effects in vivo cannot be clearly assigned
to either specific MAPK family. However, the results of compari-
son of MKP1 with MKP5 (by evaluating the levels of individual
MAPK activities inMKP1/ versusMKP5/mice) suggest that
MKP5 is more important for JNK1 dephosphorylation (75) while
MKP1 is likely more critical for p38 inactivation, at least inmac-
rophages (85). Othermembers of the dual-specificity phosphatase
family may also regulate JNK pathways by acting on upstream
signaling proteins, such as the Tab1/TAK1 complex (86) or the
focal adhesion kinase (87). Depending on their targets, the latter
phosphatases can either inhibit (MKP6/DUSP14) or activate
(MKP-x/DUSP22) JNK signaling (87–89). Hence, MKPs can also
act as either negative or positive regulators of JNK signaling.
Importantly, many MAPK phosphatases are under transcrip-
tional control by the same pathways that they inactivate. For ex-
ample, mammalianMKP1 is inducible by growth factor pathways
(90). Genetic experiments inDrosophila melanogaster suggest that
its MKP5 ortholog (Puckered) is also transcriptionally upregu-
lated by the activity of its JNK ortholog (Basket) (91), exerting
feedback control over a pathway that is essential for proper anti-
bacterial and antiparasitic responses in many insects (92). In
mammals, MKP5 expression levels may be inducible by inflam-
mation (93). Although primarily induced by p38 as part of its
feedback mechanism (94), MKP1 expression may also be at least
partially controlled by JNK actions on its transcription factor sub-
strates ATF2 and c-Jun (85, 95). However, transcriptional-level
feedback is not the only option for MAPK pathways: the JNK
pathway is also subject to feedback phosphorylation. It is known
that MLK3 and DLK can be directly phosphorylated by activated
JNK to exert positive feedback, although the exact sites andmech-
anisms differ greatly between these two proteins (44, 96). Such
positive feedback loops can result in bistable switches (97) that can
ensure immediate and robust responses by rapid, local, and max-
imal kinase activation.
Scaffold Proteins in JNK Signaling
In addition to the essential enzymatic roles played by kinases
and phosphatases within signal transduction pathways, scaffold
proteins that may lack intrinsic enzyme activities can act as pro-
tein-protein interaction hubs for multiple different enzymes to
facilitate pathway activation in the response to cell stimulation
(98–101). Before the JNKpathway scaffolds are addressed inmore
detail, it is important to appreciate that the identification and
validation of scaffold proteins can be an experimentally difficult
task. In contrast to the MAPKs themselves, which can be effec-
tively purified for further analyses, the upper-tier MAP2K and
MAP3K enzymes are frequently unstable in a purified form and
prone to spurious interactions (102, 103; A. Zeke and A. Reményi,
unpublished observations). These undesirable features of the
MAP2K and MAP3K enzymes thus necessitate rigorous testing
with positive and negative controls to assess their binding part-
ners. Furthermore, several of the proposed scaffold proteins are
also large, structurally poorly characterized proteins, so that frag-
ments may be unstable and display artificially “sticky” binding.
Therefore, the identification of JNK scaffold proteins from in vitro
studies that did not test the structural integrity of all protein part-
ners should be treated with caution. Similarly, in vitro kinase re-
actions with scaffolds can only yield biologically relevant results if
the assay conditions were carefully set, particularly with the inclu-
sion of agents (such as detergents, bovine serum albumin, or cell
protein extracts) that mitigate spurious binding and vessel wall
effects. To date,most cell-based interaction studies have used only
coimmunoprecipitation assays with overexpressed putative inter-
actors that may bias toward the detection of interactions. It is also
important to consider that the phosphorylation enhancement ef-
fects seen in cell-based studies upon the knockdown or overex-
pression of a pathway regulator may also arise from complex net-
work behavior and feedback loops rather than a traditional
scaffolding action to bring together multiple pathway compo-
nents. All of these critically important issues must be addressed
before the true importance of JNK pathway scaffolds can be clar-
ified; with these caveats in mind, the following paragraphs con-
sider the proteins currently classified as potential JNK pathway
scaffolds but focus on JIP1 as the best-described example.
Several proteins have been described to bind JNKs and one or
more of its upstream activators. These include JIP1 (104), JIP3
(105), arrestins (106, 107), filamins A and B (108, 109), RACK1
(110), Crk (111), POSH (112),WDR62 (113), DUSP19 (114), and
GRASP1 (115). Despite this interest in how scaffold proteins may
work, the structural and mechanistic details for the actions of
many of these suggested scaffolds remain unresolved (see Table S1
in the supplemental material). Interestingly, studies with mam-
malian MAPK pathway scaffolds, such as KSR1/2, hint that the
original, simple scaffolding model based on a ternary or higher-
order catalytic complex needs critical reevaluation (116). Specifi-
cally, KSR1 and KSR2 can form a complex with c-Raf or B-Raf,
enhancing their activity through dimerization-induced allosteric
activation. Furthermore, KSRs coordinate MEK1/2 as if these ki-
nases were their own substrates (i.e., in the same way as B-Raf or
c-Raf recruits MEK1/2) (117). ERK1 or ERK2 can also bind and
phosphorylate KSR proteins directly to provide negative feedback
(118). Thus, certain proteins can regulate MAPK signaling with-
out directly impacting the assembly of MAP3K-MAP2K or
MAP2K-MAPK complexes. It is important to consider whether
the reported JNK scaffolds assemble ternary kinase complexes; if
not, these proteins may be acting as complex network regulators
that enhance JNK signaling by other means. The example of the
possible actions of JIP1 (Fig. 2A), the protein first described as a
JNK pathway scaffold, is evaluated in greater detail below.
One clue in the understanding of JIP1 functions in JNK signal-
ing comes from the observation that JIP1 can bind several
MAP3Ks (MLKs and DLK) as well as MKK7 (119, 120). Further-
more, JNK-dependent phosphorylation of JIP1 can regulate not
only the release of its own upstream activators but also multiple
proteins destined for secretion (121). This influence on pathway
proteins rapidly leads to the establishment of subcellular compart-
ments where local JNK pathway activation drives a strong positive
feedback loop via JNK recruitment of its own activators through
JIP1 (Fig. 2B). Notably, in accordancewith thismodel, a high local
JNK activity was detected at the distal end of developing axons
(122). This sophisticated positive feedback loop between JNK1
and DLK could explain most of the enhancement of JNK activa-
tion following JIP1 transfection, particularly as JIP1 phospho-site
mutants could not increase pathway activation (104). Thus, the
role of JIP1 in the JNK pathway may be mechanistically very dif-
ferent from prototypical signaling scaffolds, such as the Saccharo-
myces cerevisiae Ste5 protein that increases overall signaling spec-
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ificity by binding different pathway components simultaneously
and so stimulates pathway throughput via allosteric regulatory
mechanisms (123). In addition, the mammalian MKK7 shows
high specificity for the JNKs (124–126), and so the mammalian
MKK7-JNKpathwaywould not need to rely on additional scaffold
proteins to provide pathway specificity.However, in this context it
should be appreciated that scaffold proteins may admit a number
of negative and/or positive feedback circuits to set the appropriate
level of JNK activity for different subcellular compartments and
physiological states.
In addition to these roles in JNK pathway regulation, the in-
volvement of JIP1 and JIP2 as kinesin-dependent transport adap-
tors has been supported by numerous studies (121, 127, 128). The
expression pattern of JIP1 (and the closely related JIP2) entails
the highest levels in neurons or neuroendocrine cells that have the
greatest need for large-volume axonal transport of vesicles (129).
Structural predictions and analyses of sequence conservation sug-
gest that JIP1 can approximately be divided into two halves: an
unstructured N-terminal regulatory tail and a mostly folded C-
terminal region (Fig. 2A). The last dozen amino acids of the C
terminus also appear to be intrinsically disordered and form a
kinesin light chain (KLC)-bindingmotif, allowing JIP1 to directly
couple to complexes of kinesin light chain 1 (KLC1) and kinesin 1
(130). Sequence motif analysis suggests that the structured C-ter-
minal half of JIP1 consists of at least three different domains. One
of them is a Dab/Numb-type PTB (phosphotyrosine-binding, or
protein tail-binding) domain, required for cargo binding. Like
most other PTB domains, this domain can associate with the ca-
nonicalNPxYmotifs located in the cytoplasmic tails of transmem-
brane or perimembrane proteins as well as with other motifs, but
importantly, this interaction does not require phosphorylation
within the NPxY motifs (131, 132). The immediately preceding
structured region is an Src homology 3 (SH3) domain. However,
the SH3 domain of JIP1 is unique: it is incapable of binding to
Pro-rich motifs and its purpose is to provide a specific dimeriza-
tion interface for JIP1/2 proteins. Considering that the KLC1-
kinesin 1 complexes are also dimeric, this is consistent with the
requirement for JIP1 dimerization (133). An extensive region pre-
ceding the SH3 domain also appears to be conserved and is likely
folded. While this segment shows no clear homology to other
knownprotein domains, it apparently serves as an auxiliary cargo-
binding module required to reinforce ligand recruitment by the
PTB domain (including canonical NPxY motif-containing li-
gands, such as the -amyloid precursor protein [-APP]) (134).
FIG 2 Structure and function of JIP1 acting within the JNK pathway. (A) The domain architecture of the JIP1 protein. TheN-terminal regulatory “tail” is largely
disordered, while the C-terminal half of JIP1 contains three folded domains as well as a kinesin light chain (KLC)-binding linear motif. The precise function of
the intrinsically disordered N terminus (with its conserved acidic motifs) is unknown, yet it is highly phosphorylated by JNK in a D-motif-dependent manner.
Currently, only two target sites (T103 and S421) are known to have a role in JNK-dependent physiological regulation of JIP1. This model was built by combining
domain signature searches (PFAM), folding tendency predictors (IUPRED), and conservation analyses (multiple alignments among vertebrate proteins) as well
as curated data from the literature. The lower line shows the results of conservation analyses (red, highly conserved sequence; blue, nonconserved sequence),
when sequences of vertebrate JIP1 and the closely related JIP2 proteins are aligned with each other. Structural domains and key motifs are preserved in both
proteins (including the JNK-binding D-motif), while most regulatory phosphorylation sites differ between JIP1 and JIP2. (B) A model of JIP1 actions on the
microtubule-dependent transport processes in neurons. The JIP1/2 dimers (turquoise) are capable of transporting a diverse set ofmembrane-associated proteins
(e.g., -APP, APoE2-R) as well as certain MAP2Ks (MKK7 [red]) and inactive MAP3Ks (MLK3, DLK [magenta]). These complexes are moved along the
microtubule filaments with the help of kinesin 1-kinesin light chain 1 motors (blue). At the end of their journey, the transport complexes are uncoupled by a
JNK-dependent phosphorylation of JIP1. Since this step also results in the release of upstream components and activators belonging to the JNK pathway, it leads
to a positive feedback loop and helps tomaintain subcellular compartments with high local JNK activity. The JIP1/2 proteins uncoupled from their cargo are also
transported in a reverse direction (likely through a dynein-driven process), although the structural details of the latter complex are poorly known.
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The N-terminal regulatory tail of JIP1 appears to be intrinsically
disordered. It is highly phosphorylated by JNK, and phosphoryla-
tion at Thr103 can regulate the trafficking of JIP1-cargo com-
plexes (104). As the cargo-binding domain(s) of JIP1 can also
accept transmembrane proteins (-APP, apolipoprotein E recep-
tor 2) (135) or peripheralmembrane proteins (ARHGEF28) (136)
as ligands, it is clear that JIP1 may play significant, broader roles.
JNK Nucleo-Cytoplasmic Trafﬁcking
The subcellular localization of MAPKs will dictate their access to
their substrate proteins. JNKs can directly phosphorylate many
cytoplasmic, cytoskeletal, mitochondrial, and cell membrane-as-
sociated substrates, but like many other MAPKs they were origi-
nally considered to act primarily in the nucleus through their
modulation of transcription factor actions to alter gene expression
programs. All classical MAPKs, including ERK1/2, JNKs, and the
p38 kinases, can change their subcellular localization upon path-
way activation via either preferential nuclear localization or en-
hanced nuclear retention. Although this phenomenon of in-
creased nuclearMAPKpopulations has been appreciated formore
than 2 decades, the mechanism(s) underlying MAPK nuclear en-
try and retention remains relatively poorly understood.
Most classical MAPKs (apart from ERK5) have no classical nu-
clear localization sequence (NLS) motifs for their nuclear import.
Although a phosphorylation-based NLS has been proposed for
ERK2 (137), the implicated site is not functional in JNKor the p38
kinases (138). The ERK2NLS is also problematic due to structural
reasons: the proposed site is rigidly folded and does not appear to
be available for intramolecular autophosphorylation. ERK1/2
more likely translocates into the nucleus following activation loop
phosphorylation-dependent formation of its FxFP pocket and
subsequent interactions with FxFGmotif-containing nucleoporin
proteins of the nuclear pore complex, a mechanism not possible
for JNKs (139–141). Regardless, nuclear translocation of both ac-
tive and inactive MAPKs may also be mediated by several -im-
portins. For example, importin-3, importin-7, and importin-9
have all been implicated in mediating JNK nuclear entry (138).
The use of these different importin systems could thus provide
multiple nuclear entrymodes for otherMAPKs (142) aswell as the
JNKs.
However, the movement of proteins into the nucleus may also
bemediated by complex formationwith other proteins that them-
selves have bona fide NLS motifs. For example, following coex-
pression with partners like c-Jun, JNK2 can become predomi-
nantly nuclear (143). Such piggyback transport on partner
proteins can be independent of activation state and would allow
them to form a dynamic equilibrium between the nucleus and the
cytoplasm even in the absence of JNK pathway activation. The
recent results of a predominantly -importin-dependent nuclear
import of JNK1, but in the absence of a classical NLS motif or
direct -importin binding, are consistent with this mechanism
(144). Live-cell imaging, including fluorescence recovery after
photobleaching protocols, has also revealed the constitutive nu-
cleo-cytoplasmic shuttling of green fluorescent protein (GFP)-
labeled JNK1 (144), implying that JNKs can access substrates in all
intracellular compartments rather than being restricted to a single
intracellular location. Importantly, consistent with the JNKs in-
teracting with various protein partners, these studies also revealed
a decrease in the intranuclear and intracytoplasmic JNK1 mobil-
ities following cell exposure to hyperosmotic stress (144). These
observations should prompt further studies evaluating the mech-
anisms of JNK nuclear entry and export, together with the contri-
butions played by JNK-interacting partners in modulating these
nuclear trafficking events under both normal and stress condi-
tions.
STRUCTURE AND ROLES OF DIFFERENT JNK ISOFORMS
Structural Overview of the JNKs
The human genome contains three closely related JNK genes:
JNK1, JNK2, and JNK3 (145). All three genes encode400-ami-
no-acid proteins encompassing little more than a canonical Ser/
Thr protein kinase domain (146). Within the core kinase fold,
JNKs contain several additional structural features well-conserved
among MAPKs: the CMGC insert protruding from the C-termi-
nal kinase lobe, the short common docking (CD) helix, and the
C-terminal helix binding back to the N-terminal lobe (147, 148).
Most nonvertebrate animals possess only a single JNK gene (e.g.,
Basket in Drosophila) (149); the three vertebrate JNK genes (con-
served from mammals to fish) appear to have arisen from a twin
whole-genome duplication event at the dawn of vertebrate evolu-
tion (150). Thus, the sequences and structures of all three verte-
brate paralogs are similar, with JNK2 being the earliest-branching
member as judged by the amino acid differences in its kinase do-
main (151) and JNK3 closely resembling JNK1 but with a JNK3-
specific N-terminal extension added through the use of an up-
stream translational initiation site (145).
Alternative Isoforms Encoded by Each JNK Gene
All three JNK genes encode multiple isoforms generated by tran-
script alternative splicing (Fig. 3). One such alternative splicing
site lies within the sequence specifying the C-terminal lobe of the
kinase domain; use of a mutually exclusive exon pair (the sixth
exon in most transcripts) results in two similar but not identical
kinases, termed the - and -isoforms. Unfortunately, the no-
menclature for these isoforms is not consistent, with the isoforms
incorporating exon 6a being denoted JNK1 and JNK3 but
JNK2, whereas JNK1, JNK3, and JNK2 all contain exon 6b
(see Table S2 in the supplemental material). Exons 6a and 6b are
likely the result of an ancient exonduplication predating JNKgene
duplications (152). Since the upstream intron is removed during
transcript maturation by a U2 splicing apparatus, whereas the
downstream intron is removed by a U12-type splicing apparatus,
the hybrid intron between the two exons cannot be excised with-
out eliminating one of the two exons (153). The incorporation of
alternative exons ismostly random, but it can also be controlled by
specific splicing factors. For example, the polypyrimidine tract
preceding exon 6b contains multiple binding sites for the Nova
family of neuronal splicing regulator proteins (154, 155). Thus,
the neuron-specific generation of the JNK2 isoform depends on
the proteinNova2, whichmasks the polypyrimidine tract of the 6b
exon, allowing the preferred incorporation of exon 6a instead of
exon 6b (155). Importantly, all JNK genes carry Nova-type splic-
ing regulator binding sites, but the number of these differ: JNK2,
JNK3, and JNK1 carry 5, 3, and 1 of these sites, respectively, pro-
viding a molecular rationale for tissue-specific JNK gene splicing
or the absence thereof. For all three JNK genes, the 5-nucleotide
shift that occurs with the use of a 3=-splicing site of the final intron
results in different reading frames and so produces JNK proteins
withC-terminal extensions of differing lengths. As theseC termini
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are not part of the kinase domain and are predicted to be struc-
turally disordered, their influence on the function or stability of
the individual isoforms is still unclear. However, the two splicing
variations do freely combine, giving rise to four isoforms for both
JNK1 and JNK2. Kinases with a longer C terminus are regarded as
isoform 2 (i.e., the so-called “p54” JNKs, which can include - or
-isoforms), while the shorter JNKs are regarded as isoform1 (i.e.,
the so-called “p46” JNKs, which again can include - or -iso-
forms).
In the case of JNK3, an extra ATG codon upstream of the orig-
inal initiation site can also result in an N-terminal-extended pro-
tein. Notably, this upstream initiation site lacks a Kozak sequence,
unlike the strong Kozak consensus sequence of the second ATG
codon in JNK3. This situation is a hallmark of several genes with
alternative translational initiation, hinting that JNK3 could also be
produced in short as well as long forms, even from the same
mRNA (156). The resulting JNK3N-terminal extension has a high
hydrophobic amino acid content, making it an ideal interaction
FIG 3 Splice isoforms of the JNK1, JNK2, and JNK3 proteins. (A) The structure of JNKs. The generic structure of the JNK proteins is displayed in beige
(represented by the crystal structure of JNK11; PDB ID2XRW), and the variable regions (alternative splice isoforms) are highlighted in green, red, andmagenta.
The catalytic site of the kinase domain, ATP, is indicated in yellow. Regions that are unstructured or flexible are drawnwith dotted lines. (B) All human JNKgenes
encode multiple splice isoforms. Apart from transcripts lacking a complete kinase domain (and therefore likely not yielding a functional protein), there are two
variable regions for JNK1/2 and three for JNK3. All these alternative splicing products (as well as those resulting from alternative initiation with JNK3) combine
freely and yield four isoforms for JNK1 and JNK2. For JNK3, there are 8 possible isoforms (including the longer [L] and shorter [S] N-terminal extensions), but
only 3 isoforms have been characterized to date. However, mRNA sequences from databases (such as ENSEMBL) suggest that, like JNK1/2, JNK3 also contains
the same alternative exons in its kinase domain. This hints at the existence of many more uncharacterized JNK3 isoforms (in blue). In the figure, the alternative
segments structurally and evolutionarily corresponding to each other are labeled with the same colors: red, within the kinase domain; magenta, C-terminal
flexible extension; green, N-terminal flexible extension. (C) Mechanisms of splice isoform generation in vertebrate JNK genes. The JNK3 gene has an upstream
ATG codon, resulting inN-terminally extended proteins (green). However, this upstream initiation site has noKozak consensus sequence, and so this is expected
to result in “leaky scanning” by ribosomes, allowing the translational start to stochastically shift downstream to the site shared with all other JNK proteins. All
vertebrate JNK genes have a duplicated exon (exon 6a [beige] and exon 6b [red]), where nonregulated splicing 6b is the preferred (major) exon. Their inclusion
in the final transcript is mutually exclusive with each other because of the incompatibility of their U2- andU12-recognized splicing sites. Inclusion of the 6a exon
depends on the suppression of exon 6b splicing, which can happen when the Nova2 protein binds to its polypyrimidine tract (Py) in JNK2. The ultimate splicing
site is also variable, allowing for a 5-nucleotide shift. This results in a frameshift and an early stop codon in the short (p46) isoforms, while allowing the translation
of the last exon in full in the case of the long (p54) isoforms. The sequences of the p46 (blue) and p54 (magenta) isoforms in the figure refer to JNK1. Note that
the generic intron-exon pattern (colored to match the alternative protein sequences) shown at the top is not proportional to actual intron-exon sizes. The
untranslated regions are displayed in light blue.
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mediator. Indeed, evidence ismounting that the JNK3N-terminal
extension could direct a number of unique interactionswith JNK3
(157, 158). JNK3 also differs from the other two JNK paralogs in
its expression patterns: JNK1 and JNK2 are expressed in almost
all tissues, but JNK3 expression is largely restricted to the cen-
tral nervous system. Although less studied than the other two
JNKs, JNK3 has 3 distinct isoforms confirmed at a protein level,
and at least 5 more (including the conserved, but uncharacter-
ized, JNK3 isoforms using exon 6b) only described at an
mRNA level (159). Further work is needed to define the full
JNK3 repertoire.
Lastly, in addition to mRNAs encoding full-length JNK pro-
teins, extra transcripts from all three JNK genes have also been
recorded in the ENSEMBL database (160). Even if not targeted by
nonsense-mediated decay, these shorter mRNA species would
only translate to proteins with severely truncated, structurally un-
stable, nonfunctional kinase domains. Therefore, these transcripts
may be involved in RNA-level regulation, but this awaits further
exploration.
Activities and Modiﬁcations of Individual JNK Isoforms
The enzymatic activities of JNK proteins encoded by separate
genes, or as different splice isoforms from each gene, can differ
considerably. While the addition of an overtly disordered C-ter-
minal extension would not be expected to causemajor differences
in the activities of JNKs in vitro, splicing events that swap a seg-
ment within the kinase domain, thus giving rise to the - and
-isoforms, could clearly cause a change in enzyme activity. Thus,
each splice variant can display different kinetic parameters. For
example, proteins with the 6b exon have similar Michaelis con-
stants (KM) for their common substrate ATF2, but these constants
are consistently higher than those containing the 6a exon (161).
The catalytic efficacy of phosphatases toward JNK can also be
different for the different splice isoforms: DUSP8 preferentially
inactivates exon 6a-containing JNKs, at least in vitro (162). Taken
together, these observations suggest that the individual JNK iso-
forms will likely show different enzyme activities and activation/
deactivation kinetics in vivo.
The catalytic activity of the individual JNK isoforms might also
vary on different substrates, making their roles even more com-
plex. The products of the JNK1 or JNK2 genes are markedly dif-
ferent in their ability to phosphorylate c-Jun. Notably, JNK1 ap-
pears to be far more active as a kinase acting on c-Jun: fibroblasts
and hematopoietic cells isolated from JNK1/ mice show lower
c-Jun phosphorylation and ensuing c-Jun autoinduction after
TNF- stimulation, while JNK2/mice display high c-Jun phos-
phorylation, even in unstimulated cells, due to compensatory
JNK1 hyperactivation (163, 164). The evidence from these in vivo
experiments is thus in conflict with earlier in vitro results that
indicated that JNK22 was more active than JNK11 toward c-
Jun (165). However, isoforms of both JNK1 and JNK2 actively
contribute to c-Jun phosphorylation and are at least partly redun-
dant toward most substrates (166). In neuronal tissues with mea-
surable JNK3 expression levels, JNK1, JNK2, and JNK3 all con-
tribute to c-Jun phosphorylation (167). It is also likely that
enzymes encoded by the JNK2 gene have a lower overall in vivo
activity toward other substrates (e.g., ATF2) (163). So, the picture
of different JNK enzymes fulfilling different roles is more subtle
than initially anticipated.
Additional regulatory mechanisms for the different JNK iso-
forms have also been explored. The -isoforms of JNK2 (i.e.,
JNK21 and JNK22, with exon 6b) appear to be unique in their
ability to autophosphorylate and autoactivate efficiently in the
absence of activator kinases, at least when grossly overex-
pressed in cells or assayed in vitro (168–170). Other JNK pro-
teins also retain some residual autophosphorylation activity,
but the physiological significance of such observations is not
well understood. Furthermore, the long (p54) isoforms of
JNK1 and JNK2 harbor a caspase cleavage site and their C
termini can be processed during the onset of apoptosis, with
unclear functional consequences (171). Lastly, the N- and C-
terminal-lengthened JNK32(L) isoform of JNK3 was palmi-
toylated on its C terminus by the DHHC family palmitoyltrans-
ferase ZDHHC15, which regulates JNK32(L) subcellular
localization and activity; in contrast, the almost-identical C
terminus of JNK12 was not palmitoylated (172). Taken to-
gether, these studies reinforce the differences in the potential
regulatory mechanisms for the different JNK isoforms.
Expression Patterns of JNK Genes and Splice Isoforms
The results reviewed in the preceding sections suggest an intrigu-
ing dichotomy for the - versus -isoforms of the JNKs. The
-isoforms of JNK2 (with exon 6b) are preferentially expressed in
nonneuronal tissues (155), whereas both - and -isoforms of
JNK1 are readily detectable in immune cells (173). This is consis-
tent with the sequence of their primary mRNA transcripts, with
JNK2 harboring five Nova2-binding sites in the polypyrimi-
dine tract before its 6b exon (allowing tissue-selective splicing),
whereas JNK1 has only one such site (152). The available evi-
dence, including the transcripts preferentially detected and the
multiple splicing regulator-binding sequences, suggest that the
JNK3 -isoforms are dominant over the more poorly charac-
terized JNK3 -isoforms (see Table S2 in the supplemental
material for the predicted sequence of the JNK3 -isoforms
using exon 6b).
The selection of the last 3= splicing site also differs considerably
for the JNK genes. For JNK1, there is a clear preference toward
producing mRNA encoding the shorter (p46) isoforms in both
immune cells and fibroblasts (173, 174). Conversely, JNK2 tends
to preferentially express the long (p54) isoform in the same tis-
sues. Similar patterns are seen in many other cell lineages, like the
rat adrenal medulla pheochromocytoma cell line PC12 (175). In
experiments where JNK1 and JNK2 were coexpressed, a prefer-
ence toward phosphorylation of the shorter p46 isoform was
noted across several different tissues (174, 176). However, this
preferential phosphorylationmay not reflect a difference between
JNKswith different C-terminal extensions (i.e., the long and short
isoforms) but may be related to other differences between JNK1
and JNK2 (177).
Comparison of JNK1 and JNK2 Functions In Vivo
The creation and phenotyping of different JNK knockout mice
have revealed the actions of the individual JNKs. JNK1 and JNK2
(but not JNK3) are likely to fulfill essential but largely overlapping
roles, as JNK1/JNK2 double knockouts are embryonic lethal ow-
ing to a defect in neural tube closure, but single JNK gene knock-
out, JNK1/JNK3 double knockout, or JNK2/JNK3 double knock-
out mice were viable (178, 179). However, important differences
between JNK1 and JNK2 in terms of their contributions to cellular
regulation could be inferred from the differences in the pheno-
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types of the JNK1/ and JNK2/mice. Specifically, the pheno-
type of JNK1/ mice was more marked, with abnormalities in
brain development (abnormal cortical neuronal migration and
anterior commissure degeneration) as well as disturbedmetabolic
regulation (including resistance to obesity and obesity-induced
metabolic changes) (180, 181). Conversely, JNK2/mice showed a
less remarkable phenotype, with epidermal hyperplasia and mild
immune abnormalities (182). Furthermore, different JNK gene
knockout mice showed that JNK1 and JNK2 regulate fibro-
blasts, macrophages, and T cells differently (163, 183, 184) and
also influence skin wound repair differently (185). Neurogen-
esis in vitro also primarily requires JNK1, but not JNK2 or JNK3
(186). Maintenance of metabolic homeostasis required both
JNK1 and JNK2, but JNK1 played more important roles (187).
These studies reinforce the different roles played by the differ-
ent JNKs.
The compensatory JNK1 hyperactivation and thus paradoxi-
cally higher c-Jun phosphorylation observed in JNK2/ mice
may help to explain some of the different observations for
JNK1/ and JNK2/mice, such as altered cell cycle regulation
(164). That the extent of JNK2 phosphorylation is consistently
lower than JNK1 phosphorylation under normal conditions may
be due to differences in their activation loops (177). Nevertheless,
there are several tissues and experimental models where the ac-
tions of JNK1 and JNK2 are cooperative or synergistic. Examples
include the development of skin keratinocytes (188), spiral
ganglion neurons (189), or the differentiation of pluripotent
embryonic cells, where both JNK1 and JNK2 were required for
establishing mesodermal and epithelial lineages (190). UV- or
arsenite-induced apoptosis of fibroblasts required both JNK1
and JNK2 (191, 192). In addition, lipolysis in adipocytes was
also regulated by JNK1 and JNK2 (193). The results of these
studies suggest that the different JNKs can act in a concerted
manner in some cell and stimulus contexts.
Greater attention has also been directed toward the study of
JNK1/mice in the area of tumor biology. JNK1/mice spon-
taneously developed intestinal tumors, consistent with the roles of
JNKs as negative regulators of cell proliferation and their proapo-
ptotic actions in many cell types (194). In several carcinogenesis
models, such asUV- or phorbol ester-induced skin tumorigenesis,
JNK1/micewere alsomore prone to developmalignant tumors
(195). However, JNK1 is not a clear tumor suppressor: in cases
such as nitrosamine-induced gastric and hepatic tumorigenesis,
JNK1/mice were less responsive, suggesting that JNK1 may be
required for tumor development (196). Also, the combined ac-
tions of JNK1 and JNK2 have been implicated in the proliferation
of glioma cells (197). The underlying causes for these different
outcomes remain unresolved, but some researchers have pro-
posed a regeneration-based model as the basis of enhanced
tumorigenesis, especially in the liver (198). As JNK1/ mice
show less apoptosis leading to the same cytotoxic insult, they
consequently require lower hepatocyte regeneration and thus
fewer cell divisions. This reduced proliferative requirement,
relative to the higher numbers of proliferating cells exposed to
genetic damage in wild-type animals, may help to protect
against genotoxic stress. However, it also remains possible that
JNK1 and/or JNK2 enhances the survival and metastatic ability
of certain malignant cell types in a tissue-specific and/or tu-
mor-specific manner.
JNK RECOGNITION OF ITS PARTNER REGULATORS AND
SUBSTRATES
Docking Motifs (D-Motifs) Are a Dominant Molecular
Solution in JNK Recruitment
The MAPKs, including the JNKs, are classified as Pro-directed
Ser/Thr kinases: the Ser/Thr residues targeted for phosphoryla-
tion by these kinases usually are followed immediately by a Pro
residue. Although such Ser/Thr-Pro (i.e., Ser-Pro/Thr-Pro [SP/
TP]) sites are extremely common in all proteins, only a fraction
will likely be bona fideMAPK substrates. This specificity is attrib-
uted to docking motifs within targeted substrate proteins that
bind to dedicated sites on the kinase domains of MAPKs (199).
The most commonly used kinase domain docking site consists of
the negatively charged common docking (CD) region and the hy-
drophobic groove, commonly referred to as the docking groove,
which binds to the so-called substrate D-motifs (a name derived
from the D region of Elk1 and the 	 segment of c-Jun) (Fig. 4).
MAPK substrate D motifs are short linear motifs of 9 to 18
amino acids found in the disordered segments of proteins, often
(but not always) N-terminal from the targeted phosphorylation
sites (200). As the catalytic site and the D-motif docking groove
are spatially separated on the kinase domain, the phospho-target
motif must also be separated by aminimal number of amino acids
(9) from the D-motif for efficient coupling (201). However,
other MAPK partners, not only substrates, utilize D-motifs as a
molecular solution to recruit MAPKs. Thus, the same binding site
is also used by MAP2Ks to access their MAPK partners, many
phosphatases responsible for the inactivation of MAPKs, and a
wide variety of pathway regulators/scaffolds. These interacting
partners thus all compete for the same interaction “hot spot” on
the MAPKs. Although the D-motifs are structurally variable, the
structural basis ofMAPK-partner protein specificity is well under-
stood. It is now becoming increasingly clear that themotifs direct-
ing association with JNKs are often specific and distinct from
docking motifs targeting other MAPKs. For example, the set of
p38 substrates and partners substantially overlaps with those of
the mitogen-activated ERK1/2, but not with JNKs (200). This
phenomenon is also likely to have network-level implications
for the stress-activated MAPKs, because JNKs and p38 kinases
could control different sets of stress-activated proteins by
phosphorylation.
In recent years, many novel JNK partners (mostly substrates)
have been identified based on the presence of D-motifs, and their
number is expected to grow (69). JNK-associating D-motifs can
be separated into at least two, structurally different varieties: either
resembling the D-motif found in the JNK pathway regulator JIP1
or resembling the motif described for the NFAT4 transcription
factor (80, 200) (Fig. 5; see also Table 1 for a summary of D-motif
types in known JNK substrates). These two motifs interact with
the same region of JNKs but are not equivalent structurally due to
the differences in the relative positioning of their hydrophobic
and charged residues. While most examples of these JIP1- or
NFAT4-type docking motifs have been described in JNK1-inter-
acting proteins, the docking surfaces of JNK1, JNK2, and JNK3 are
near identical. That the interaction interfaces for the different
JNKs will be very similar is supported by the structures of JNK3-
JIP1 and JNK3-Sab complexes, which are nearly identical to the
JNK1-JIP1 complex (202). The sameD-motifs for JNK1 and JNK3
(at least for the short splice isoforms) also are likely to function
Zeke et al.
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equally well (158). Although the docking groove lies next to the
“hinge” connecting the N and C lobes of the kinase domain and
D-motif binding may exert some allosteric changes on the kinase
domain (203), it is likely that the JNK docking groove is avail-
able for D-motif binding in all activation states of the kinase
domain. As a consequence, it is expected that many of the same
binding partners interact with JNKs in both active and inactive
conformations.
In addition to D-motifs located in flexible protein regions of
partner proteins, other domains or linear sequences may direct
MAPK-partner interactions. Although folded domains have
also been described to interact with the MAPK docking groove,
for example, in the p38-MKP5 complex (204), it is still an
open question whether JNK has similar structured domain
partners. The elucidation of such complexes will require sub-
stantial structural efforts directed toward defining modes of
interactions of the JNKs with partners that are apparently de-
void of the conventional D-motif consensus sequences. In ad-
dition, substrates can also be recruited by most MAPKs via
their FxFP site that is located in between the phosphorylated
activation loop and the CMGC insert. This site was named
based on the optimal consensus of linear motifs targeting it in
the case of ERK2; the FxFP-site of JNK1 likely prefers substan-
tially different motifs, as peptide arrays testing the original
Phe-x-Phe-Pro motif failed to identify any strong JNK binders
(203). However, other assays using artificial substrates de-
FIG 4 Structural features and substrate recognition by JNKs. (A) JNK proteins are comprised of a single protein kinase domain (structure on the left). The
docking site, consisting of the negatively charged CD region (blue) and the hydrophobic docking groove (beige), plays an important role in partner binding and
recruitment of substrates (red). The phosphotransfer reaction fromATP (yellow) takes place at the opposite side of the kinase, where the catalytic residues (pink)
are located. Apart from the docking site, the CMGC insert (orange) is also unique to the MAPKs and a few related protein kinases. This also harbors a docking
surface called the FxFP site. Although known to be functional in other MAPKs, no FxFP site-dependent substrates have been identified for JNK. The figure is
based on the complex of human JNK1 with a docking motif from NFAT4 (PDB ID 2XRW). The peptide chain modeled at the catalytic site is based on the
DYRK1A-substrate complex (PDB ID 2WO6;DYRKs are closely related toMAPKs in structure as well as in substrate preference). The rest of the substrate, which
is not associated with JNK, is indicated with a dotted red line. Together, the CD region and the docking groove form the major docking site (D-site) of JNK
proteins and play a key role in substrate recruitment (shown on the right). The best-characterized substrate proteins either contain a linear motif capable of
interacting with the D-site directly (direct substrates [top]) or interact with a third protein having such a motif through heterologous interactions (indirect
substrates [bottom]). (B) JNKs bind most of their known partners by engaging a dedicated recruitment site (D-site) that is distinct from their catalytic site. The
same docking site is used to interact with activator kinases (MAP2Ks) responsible for the phosphorylation of the JNK activation loop, with phosphatases that
dephosphorylate the same residues, as well as with other proteins involved in the regulation of pathway through intracellular compartmentalization and
multiprotein complex formation (i.e., scaffolds). Many substrates also utilize the same docking site to provide access to the kinase. Therefore, most partners of
JNKs directly compete with each other for binding and access to the catalytic site. Abbreviations: D, docking motif; K, kinesin-binding motif of JIP1.
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signed to include docking domain peptides suggested that the
FxFP site of JNKs is still functional (201); recent structural
studies indeed suggest that this site mediates JNK1 interaction
with the dual-specificity phosphataseMKP7 (81). Despite these
alternative modes of interactions with the MAPKs, most JNK
interactors use typical D-motifs to partner with JNKs (80).
Multiprotein Complexes and the Prevalence of JNK
Substrates in Trans
Many of the reported JNK substrates lack the typical JNK-
binding motifs or domains described in the preceding section
(Table 1), but many of these substrates do form complexes
either with each other or with proteins that do possess JNK-
binding motifs. For example, the cooperation between differ-
ent AP-1 proteins in JNK recruitment is well-known (205);
AP-1 transcription factors and certain nuclear receptors com-
monly occupy adjacent positions in promoters (206, 207).
Many leucine zipper transcription factors, including Jun and
ATF2, can heterodimerize with each other in a combinatorial
manner (208), whereas other JNK substrates, such as YAP1 and
p73, are also direct binding partners (209). In these examples,
the recruitment of JNK into larger transcription factor com-
plexes enables JNK-mediated phosphorylation of multiple
transcription factor protein substrates.
Inside the nucleus, the restriction of JNK activity to certain
chromosomal sites opens up the possibility for the same protein to
be regulated by one MAPK on one promoter but not on another.
Such JNK-regulated complexes may also have dedicated protein
components: the histone-like pioneer transcription factor NF-Y is
FIG 5 The twomain classes of D-motifs that interact with JNKs.Most of the known JNK-interacting D-motifs (located in diverse partners) belong to one of two
distinct structural types, corresponding either to the JIP1 or to the NFAT4 consensus motifs (top). These two structural classes can be described with related,
though different, consensus motifs (middle). Despite the differences, all these motifs bind to the same docking site. A large number of known JNK interactors,
togetherwith their evolutionarily closely related paralogs, harbor dockingmotifs showing sequence similarity to either the dockingmotif of JIP1 or to the docking
motif of NFAT4 (bottom panels). Many of these docking motifs were characterized in in vitro experiments only, a few motifs do not satisfy the complete
consensus, and some proteins (e.g., BMPR2, ATF2, ATF7, MKK7) contain more than one motif of the same or different type. (Structural panels were made by
using crystal structures of JNK-peptide complexes: PDB IDs 4H39, 4H3B, and 2XRW for JNK3-pepJip1, JNK3-pepSab, and JNK1-pepNFAT4, respectively.)
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TABLE 1 Summary of JNK substratesa
Protein functional group and nameb Function
No. of JNK target
phospho-sitesc
D-motif
typec
Suppl.
table(s) Reference(s)
1. Transcription, DNA and chromatin
regulation
ATF2# Transcription factor 2 B S3 164, 230
Beta-catenin Transcriptional coactivator 2 (
2) D S5, S6 270, 272, 471
c-Jun# Transcription factor 4 B S3 224, 229
Cdt1 DNA replication factor 3 D S5 252
Elk1# Transcription factor 2 A S3 472, 473
Elk3 Transcription factor 4 C S4 343
Elk4 Transcription factor 6 C S4 474
FOXO3 Transcription factor 1 D S5 236
FOXO4 Transcription factor 2 D S5 235
Gli1 Transcription factor 1 C S4 69
Gli3 Transcription factor 1 C S4 69
Hes1† Transcription factor 1 D S5 232
HSF1‡ Transcription factor 1 B S3 316
JDP2# Transcription factor 1 D S5 475
JunD# Transcription factor 3 B S3 476
Myc# Transcription factor 2 D S5 231
NFAT1 (NFATc2) Transcription factor 2 D S5 309
NFAT2 (NFATc1)‡ Transcription factor 1 D S5 308
NFAT4† Transcription factor 2 B S3 307
NF-E2 Transcription factor 1 (
1) D S5, S6 471
Nrl# Transcription factor 1 D S5 347
p53 Transcription factor 1 D S5 238
p73† Transcription factor 6 D S5 239
RRN3 (TIF1A) Transcription factor 1 D S5 477
Sirtuin Histone deacetylase 1 (
1) D S5, S6 253, 254
Smad2# Transcription factor 2 D S5 478, 479
Smad3# Transcription factor 2 D S5 478, 479
Sp1† Transcription factor 2 D S5 234
STAT1 Transcription factor 1 D S5 480
STAT3 Transcription factor 1 D S5 481
Twist1† Transcription factor 1 D S5 233
YAP1† Transcriptional coactivator 4 D S5 246
POU6F1 (TCF-1) Transcription factor (2) D S6 482
Histone H3.1 Histone (DNA packaging) (1) D S6 483
Runx2 Transcription factor (1) D S6 484
2. mRNA splicing and translation
DCP1a mRNA decapping enzyme 1 D S5 255
eEF12 Elongation factor 1 (
1) D S5, S6 259
hnRNPK† RNA-binding protein 3 C S4 256
SP45 RNA-splicing factor 1 D S5 258
AIMP1 tRNA synthase regulator (1) D S6 485
3. Receptors and sensors
Androgen receptor† Nuclear hormone receptor 1 D S5 240
Glucocorticoid receptor† Nuclear hormone receptor 1 D S5 241
GluR2† Receptor ion channel 1 D S5 288
GluR4† Receptor ion channel 1 D S5 288
LRP6 Wnt coreceptor 1 D S5 486
LSR (angulin) Lipoprotein receptor 1 D S5 487
Nur77# Nuclear hormone receptor 1 D S5 488
PPAR‡ Nuclear hormone receptor 1 D S5 242
RAR# Nuclear hormone receptor 3 D S5 243
RXRd* Nuclear hormone receptor 4 D S5 244, 245
SREBP1 Lipid sensor 2 D S5 489
(Continued on following page)
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TABLE 1 (Continued)
Protein functional group and nameb Function
No. of JNK target
phospho-sitesc
D-motif
typec
Suppl.
table(s) Reference(s)
4. Protein phosphorylation and
dephosphorylation
Akt1 Protein kinase 1 D S5 490
DLK Protein kinase 4 (
1) D S5, S6 44
DUSP8 (M3/6) Protein phosphatase 3 D S5 491
S6K (p70RSK)# Protein kinase 2 D S5 333
PPM1J# Protein phosphatase 3 A S3 69, 71
Cdc25B Protein phosphatase 2 D S5 492, 493
Cdc25C Protein phosphatase 1 D S5 494, 495
Raptor Protein kinase regulator 3 D S5 496
14-3-3-* Phospho-protein adaptor 1 D S5 285, 359
14-3-3-* Phospho-protein adaptor 1 D S5 285
MST1 Protein kinase (1) D S6 497
RSK Protein kinase (1) D S6 498
5. Diverse scaffolds and adaptors
DLG4 (PSD-95)† Synaptic scaffold protein 1 D S5 287
eIF4ET Nucleopore shuttling protein 6 D S5 499
IRS1† Receptor-associated scaffold 1 A S3 273
IRS2† Receptor-associated scaffold 1 A S3 274
Paxillin# Cell adhesion receptor and
cytoskeletal protein
1 D S5 268, 269
Shc1 Receptor-associated scaffold 1 D S5 500
LIMD1 Multipurpose adaptor (2) D S6 501
6. Other signaling systems
cPLA2 Phospholipase 1 D S5 502
DAT1 (SLC6A3) Dopamine transporter 1 D S5 503
eNOS* Nitric oxide synthase 1 D S5 358
ITCH‡ E3 ubiquitin ligase 2 D S5 319, 504
Rad18 E3 ubiquitin ligase 1 D S5 250
Aquaporin-2 Water channel (1) D S6 505
CDKN1B (p27Kip1) Cyclin/Cdk inhibitor (1) D S6 506
(SMPD2) Sphingomyelin phosphodiesterase (1) D S6 507
7. Cytoskeletal proteins
Cytokeratin-8‡ Cytoskeletal protein 1 D S5 310
DCX† Microtubule-associated protein 3 B S3 260–262
MAP2† Microtubule-associated protein 3 D S5 264
MARCKSL1† Actin-binding protein 3 D S5 266
SMTL2# Actin-binding protein 4 A S3 267
Stathmin 1 Microtubule-associated protein 2 C S4 508
Stathmin 2 (SCG10)# Microtubule-associated protein 2 C S4 509
Taue# Microtubule-associated protein 3 D S5 265
WDR62† Microtubule-associated protein 3 B S3 213
KIF5C (kinesin) Motor protein 1 D S6 510
Moesin Cytoskeletal anchor protein (1) D S6 511
Stathmin 3 (SCLIP) Microtubule-associated protein (1) D S6 508
8. Vesicular transport
APLP2 Vesicular transport receptor 1 D S5 217, 512
-APP# Vesicular transport receptor 1 D S5 217
JIP1† Vesicular transport adaptor 7 A S3 104
JIP3† Vesicular transport adaptor 3 A S3 275
Synaptotagmin 4 Vesicle fusion protein 1 D S5 513
9. Mitochondrial control of apoptosis
Bad‡ BH3 only protein 1 D S5 303
Bax Mitochondrial pore regulator 1 D S5 514
Bcl2‡ Mitochondrial pore regulator 3 D S5 305
(Continued on following page)
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surprisingly a better predictor of JNK presence on the chromatin
than canonical AP-1 complexes themselves (210). Again, this may
not require NF-Y (which lacks any obvious JNK-binding motifs)
to recruit JNKdirectly: itmay be an obligatory protein component
of JNK-regulated, phospho-AP-1-containing promoter com-
plexes (211). That the histones themselves can also be phosphor-
ylated by JNK around this assembly may allow further enhance-
ment of gene expression (210). This nano-environment of a
chromatin-bound multiprotein complex, with its own combina-
tion of JNK-regulated proteins, remains an intense focus of re-
search (reviewed in reference 212).
Compartmentalization effects may also apply to phosphoryla-
tion events outside the nucleus. Cytoskeleton-associated JNK
partner proteins or microtubule-binding proteins targeted by
JNK contain diverse structural features, such as double WD40
domains (in WDR62 and MABP1), tandem doublecortin do-
mains (inDCX andDCLK), orMAP2 repeats (in Tau andMAP2),
whichmay allow them to be recruited onto the surface of the same
microtubule, possibly even engaging adjacent sites (213–216).
However, only a fraction of these proteins carry dedicated JNK-
binding motifs (e.g., WDR62, MABP1), so that the rest (e.g.,
MAP2, Tau) may rely on their spatial proximity to these partners
to be phosphorylated by JNK. Similarly, theMINT2 (APBA2) pro-
tein, distantly similar to JIP1 and JIP2, enables JNK-mediated
phosphorylation of -APP with a possible impact on the regula-
tion of amyloid  production (217).
In summary, multiprotein complexes only need a single mem-
ber to recruit JNK via a typical JNK docking D-motif to catalyze
the phosphorylation of accessible SP/TP sites on other members
of the complex. Thus, docking motifs are instrumental to recruit-
ment of JNKs into diverse subcellular compartments and macro-
molecular complexes. As a consequence, many substrates can be
indirect (i.e., lacking the kinase recruitmentmotif characteristic of
direct substrates), using heterologous interactions in encounters
with activated JNKs. The prevalence of indirectly recruited sub-
strates may also conveniently explain certain peculiar protein ar-
chitectures. The transmembrane receptor BMPR2 presents an ar-
ray of two JIP1-type docking motifs but contains relatively few
conserved JNK target sites, suggesting that other BMPR2-interact-
ing proteins may be the targets of JNK-mediated phosphorylation
(218).
THE MANY SUBSTRATES OF JNK: 20 YEARS AND STILL
COUNTING
Substrate Speciﬁcity of JNKs
Since the description of the JNKs as the kinases responsible for
c-Jun phosphorylation, many additional JNK substrates have
been described (Table 1). The consensus constructed from the
well-validated JNK substrate sites curated from the available pub-
lished literature, which deals mostly with JNK1-mediated phos-
phorylation (176 sites in 89 proteins) (Table 1; see also Tables S3
to S5 in the supplemental material for additional detailed infor-
mation), reinforces the preference by JNKs to target Ser/Thr res-
idues followed by a Pro, i.e., according to the standard nomencla-
ture in which the phosphorylated site is the P0 position, JNK has a
requirement for Pro at the P 
 1 position and so prefers SP/TP
motifs (see Fig. S1A in the supplemental material). The over-
whelming similarity of the JNK catalytic sites suggests almost
identical substrate preferences for all 3 JNKs, and this is reinforced
by an analysis of the experimentally determined phosphorylation
sites (see Fig. S1A in the supplementalmaterial). The substrate site
specificity of JNK2 as directly measured with oriented peptide
libraries again indicates that there is practically no constraint
other than a Pro following the Ser/Thr targeted for phosphoryla-
tion (203). Furthermore, as JNK2 does not display any preference
TABLE 1 (Continued)
Protein functional group and nameb Function
No. of JNK target
phospho-sitesc
D-motif
typec
Suppl.
table(s) Reference(s)
Bim‡ BH3-only protein 3 D S5 302
Mcl1 Mitochondrial pore regulator 2 A S3 281
Noxa (PMAIP) BH3-only protein 1 D S5 515
Bid BH3 motif protein (1) D S6 516
SMAC (Diablo) Ubiquitin ligase inhibitor (1) D S6 517
10. Unknown
Sab (SH3BP5) Mitochondrial, possible scaffold 1 A S3 378, 518
a The table presents JNK substrate proteins (104 in total; 89 well-validated JNK substrates [indicated in regular font] and 15 less-well-validated JNK substrates [indicated in italics]),
listed alphabetically within each of the 10 major functional groupings (see Fig. S1 in the supplemental material for representations of these groupings for the 89 comprehensively
and well-validated proteins). In addition to protein function, the number of characterized JNK target phosphorylation sites (again with well-validated information indicated in
regular font and less-well-validated values indicated in italics) and the D-motif type are presented (this information represents a summary of the more-detailed information
presented in Tables S3 to S6 in the supplemental material). Of these substrates, features of the interaction site with JNK have been defined for 23 protein substrates: 9 with a JIP1-
like site (class A), 7 with an NFAT-like site (class B), and 7 with a weak, incomplete, or atypical binding sequence (class C). Class D sites are uncharacterized. The ratios of known
JNK target sites per protein are 1.98 for all well-validated JNK substrates (i.e., 176 sites in 89 proteins), 2.70 for well-validated protein substrates possessing a known JNK-binding
D-motif (i.e., 62 sites in 23 proteins), and only 1.73 for the well-validated protein substrates devoid of known D-motifs (i.e., 114 sites in 66 proteins).
b Commonly used protein names and/or their commonly used acronyms are listed; when a protein is well known by1 name, the alternative is presented in parentheses. Within a
framework of understanding the immediate molecular consequences of JNK-mediated phosphorylation of these substrates, the following symbols indicate the impact of the
indicated protein: ‡, negative phospho-switch (i.e., phosphorylation to negatively regulate protein-protein interactions or intramolecular interactions); #, positive phospho-switch
(i.e., phosphorylation to positively regulate protein-protein interactions or intramolecular interactions); *, allosteric phospho-switch; †, a less-understood impact, including
complex changes such as impacts on intracellular localization, as discussed in the text.
c The total number of validated JNK target sites is indicated (additional possible sites are indicated in italics and parentheses). See the indicated table(s) in the supplemental material
for further information (and also on D-motif classification, where indicated).
d In addition, RXR can be subjected to more complex regulation (245).
e In addition, Tau can be subjected to more complex regulation (354, 355).
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for Pro in the P-2 position (i.e., a Pro positioned 2 residues imme-
diately N terminal to the target Ser/Thr residue), its selectivity is
lower than that of ERK2 or p38, which prefer a P-X-[S/T]-P
motif (203). Furthermore, like other MAPKs, JNKs may phos-
phorylate target sites of SA, TA, SS, TS, ST, or TT (where the first
residue, underlined, is the target of phosphorylation), yet at a
much lower rate than the SP/TP sites; SG or TG sites are still
allowed, but amino acids with large side chains are strongly disfa-
vored or completely forbidden at the P
 1 position (203).
Challenges for JNK Substrate Identiﬁcation and Validation
More than 100 proteins have now been reported as JNK substrates
(Table 1; see also Tables S3 to S6 in the supplemental material for
more detailed summaries). Although JNKs have been studied in-
tensively for more than 2 decades, the identification of their sub-
strates is still not a simple task.Most difficulties stem from the low
stringency of JNKs toward their phosphorylation target sites. Be-
cause SP/TP consensus sites are common in all proteins, in vitro
kinase assays performed with purified proteins are usually not
informative: with supraphysiological amounts of activated JNKs,
many such sites can be efficiently phosphorylated in vitro, regard-
less of the physiological situation within cells where MAPK-de-
pendent phosphorylation is further constrained by compartmen-
talization and/or dedicated recruitment effects. If used in overtly
high quantities, JNKs may phosphorylate several suboptimal
(non-SP/TP) sites.
In addition, many SP/TP sites can be targeted by MAPKs or by
a plethora of other related kinases, including GSK3 and CDKs, as
well as DYRKs, HIPKs, IKKs, or even mTOR. Thus, a single site
may be potentially modified by multiple different kinases, acti-
vated by different signaling events, adding a further layer of com-
plexity to physiological regulation. Selective inhibitors can be
helpful in this case to differentiate between kinases with similar
substrate site preferences. However, even inhibitors described as
“specific” for a given kinase should be used with caution because
slightly higher concentrations may still have the potential to in-
hibit all structurally related kinases. In addition, “specific” inhib-
itors may act against other less-studied protein kinases equally
well. For example, the commonly used “JNK1/2-specific”
SP600125 (219) showed comparable inhibitory activities against
SGK1, PDK1, Aurora B and C, CK1	, MELK, DYRK2, and
DYRK3 (Kinase Inhibitor Database; http://www.kinase-screen
.mrc.ac.uk/kinase-inhibitors) (220). Peptide or peptido-mimetic
inhibitors based on the initial domain-mapping experiments for
JIP1 (221), such as the cell-penetrating TI-JIP (interfering with
JNK activation by MAP2Ks as well as its targeting to substrates
[222]) or its retro-inverso analogs (223), have less favorable phar-
macokinetic properties but are expected to be more specific to-
ward JNKs. Thus, only a combination of different approaches will
achieve a desired selectivity in targeting JNKs to facilitate a better
understanding of the relationships between JNKs and possible
physiologically relevant substrates.
A striking observation for many of JNK substrates is that they
possess more than one phosphorylation site that can be targeted
for phosphorylation by JNKs (Table 1 provides a summary of the
data regarding an average of 1.98 sites/substrate protein, repre-
senting 176 sites in 89 well-validated protein substrates). These
multiple phosphorylation sites may reflect several possible regu-
latory mechanisms under the control of JNK activity. It may be
that only 1 or 2 of these sites will be critical for the regulation of a
given physiological function, but the same protein can also have
multiple regulatory sites, each performing different, and some-
times even opposing, roles (224). Furthermore, the sites may be
phosphorylated in a specific order; this processive phosphoryla-
tion (in which phosphorylation events at distinct sites occur with-
out the dissociation of the enzyme from its substrate) is a common
situation for enzymes such as the Src-family tyrosine kinases,
which also rely on additional substrate recruitment sites, such as
SH2 domains (225–227).
Studies using engineered mutants in the phospho-sites of the
substrates under investigation (i.e., [S/T]¡ A or [S/T]¡ E mu-
tants) can be invaluable in the validation of phosphorylation or
give hints on their physiological effects. However, the mapping of
critical regulatory sites can be complicated, because the pheno-
types of multisite [S/T]¡ A or [S/T]¡ E mutants are typically
not informative enough to decipher molecular-level regulatory
switches, necessitating single-site scanning. If the site in question
is subject to complex, multistep regulation (such as phosphoryla-
tion-dependent ubiquitinylation or SUMOylation), then the phe-
notype will also depend on the experimental conditions used. For
example, paradoxical stabilization effects were described when
several phosphodegron systems were manipulated, potentially
due to substrate-specific competition between enzymes (228).
Finally, a bona fide phosphorylation site cannot be confirmed
only by obtaining a phenotype after mutating an SP/TP site; the
region could participate in phosphorylation-independent interac-
tions or may be a structurally important feature in an otherwise-
kinase-inaccessible folded domain. Thus, the array of potential
JNK substrates defined in the current published literature should
be treated with some caution, especially in the absence of multiple
independent lines of evidence for true enzyme-substrate relation-
ships.With this caveat inmind, we present here an overview of the
major classes of proteins targeted by JNKs before we discuss in
greater detail the established roles for JNKs inmediating a range of
physiological and pathological events.
Major Classes of Proteins Targeted by JNKs
The archetypical substrates of JNK are a diverse assortment of
transcription factors (summarized in Table 1; see also Tables S3 to
S6 in the supplemental material for details regarding the JNK-
mediated phosphorylation and docking site sequences). These
JNK substrates encompass members of many different families,
including those of the bZIP (Jun, ATF2, Myc [164, 224, 229–
231]), bHLH (Hes1, Twist1 [232, 233]), Zinc finger (Sp1 [234]),
Forkhead (FOXO4, FOXO3 [235–237]), and RUNT (p53, p73
[238, 239]) families, as well as proteins of the nuclear receptor
family (androgen receptor, glucocorticoid receptor, peroxisome
proliferator-activated receptors, RAR, and RXR [240–245]).
Coactivators and corepressors lacking a direct DNA-binding ca-
pacity (such as YAP1 [246]) can also be targeted by JNK.
By acting on these nuclear transcription factor substrates (Table
1 provides a summary of the complete list, including 30 well-
described transcription factor or transcriptional activator protein
substrates and 2 with less-strong supporting evidence, in addition
to 5 nuclear hormone receptors), JNKs can effectively regulate
transcription ofmany target genes. These are required not only for
adaptation to stress stimuli or apoptosis, but also for embryonic
development. However, at a molecular level, most transcription
factors (even those that are closely related) can be regulated by
different mechanisms. Notably, a number of their target genes
Zeke et al.
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encode proteins that are also JNK substrates themselves (e.g., c-
Jun, p73, YAP1), allowing multilevel regulation of the same pro-
tein by JNK via both transcriptional and posttranslational mech-
anisms (247, 248). With 1,000 annotated transcription factors
in the human genome (249), this list of JNK targets is likely still far
from complete. Indeed, JNK may also phosphorylate many more
transcription-associated targets, including the PPAR receptor
coactivator PGC1, the transcription factors TSHZ3 and HSF4,
and the nuclear receptor signaling regulator KANK2 (80). Taken
together, these observations reinforce a prominent role for nu-
clear JNKs as transcriptional regulators (see Fig. S1B and C in the
supplemental material).
Despite the importance of transcription factors as JNK sub-
strates, not all DNA-binding JNK substrates are transcription fac-
tors (Table 1). Indeed, JNK can also phosphorylate proteins that
participate in DNA repair (RAD18), DNA replication (Cdt1), or
DNA packaging (via regulation of the histone deacetylase sirtuin)
(250–254). Furthermore, JNK can also influence gene expression
through phosphorylating proteins involved in mRNA splicing or
other components of the translational machinery that impact on
the use of the gene transcripts and their ultimate production of
products (including DCP1a, heterogeneous nuclear ribonucleo-
protein-K [hnRNP-K], SP45, and the -subunit of eukaryotic
elongation factor 1A2 [eEF12]) (255–259).
Although most research groups have followed a “MAPK-de-
pendent gene expression” paradigm by focusing on JNK nuclear
substrates, further evaluation of nonnuclear proteins may reveal
additional JNK substrates, a notion supported by the prevalence
of D-motifs in diverse cytoskeleton-regulating proteins (80). In-
deed, numerous JNK substrates are found outside the nucleus (see
Fig. S1B in the supplemental material for an overall summary of
intracellular localizations of the 89well-validated JNK substrates).
For example, cytoskeletal and intracellular transport proteins are
also important JNK substrates (Table 1; see also Fig. S1C). These
cytoskeletal JNK substrate proteins include those associating
with microtubules (DCX [260–262], MAP1B [180, 263], MAP2
[264], Tau [265], and WDR62 [213]), the actin cytoskeleton
(MARCKSL1 [266] and SMTL2 [267]), or focal adhesions (paxil-
lin [268, 269] and -catenin [270–272]). In addition, JNK-medi-
ated phosphorylation of additional proteins may also direct vesic-
ular transport (through phosphorylation of JIP1 and -APP [104,
217]), as well as the exocytosis of specialized, Glut4-containing
vesicles (through insulin-stimulated phosphorylation of IRS1 and
IRS2 [273, 274]). Also, it can potentially control Rho-family small
G-proteins involved in this process (through JIP3 [275]). Since
JNK is implicated in the control of cell migration, especially in the
developing central nervous system (276), the purpose of JNK-
dependent regulation of diverse cytoskeletal proteins can be un-
derstood in this context. Additionally, JNK is an important regu-
lator of cell-cell adhesion. For example, JNK activation can lead to
changes in epithelial morphology, adherens, and tight junctions
(277, 278). Recent studies have implicated many more JNK target
proteins in these processes, including Rho-family small G-protein
activators (DOCK5, DOCK7), Rab-family G-protein partners
(MADD, RUSC2), vesicular transport adaptors (APBA2/MINT2),
actin filament assembly proteins (Formin1, FHOD3), microtu-
bule-associated proteins (CCSER1), and molecular motors (My-
osin-9B) (80, 158). These additional potential targets therefore
await further testing and validation.
JNKs are also important for the promotion of apoptosis in spe-
cific cellular contexts through its phosphorylation of apoptosis-
regulating proteins of the Bcl2 family of mitochondrial pore-
forming proteins (279–283) (Table 1). Antiapoptotic proteins like
Mcl1 and Bcl2 are targeted by JNK similarly to their proapoptotic
partners (such as Bad or Bim), as it controls them by diverse mo-
lecularmechanisms (284). JNK activation can also influence other
signaling pathways (Table 1). Insulin receptor signaling (where
JNK-mediated phosphorylation of IRS1/2 inhibits the action of
insulin) is one prominent example (273), whereas JNK may also
more generally antagonize Akt/PKB-dependent signaling (285).
These cross-regulationmechanisms are likely most critical during
embryonic development due to JNK-dependent control of devel-
opmental signaling pathways. JNKs, activated as part of the non-
canonical Wnt and TGF-/BMP pathways, can provide feedback
within these pathways; for example, the bone morphogenic pro-
tein receptor BMPR2 is a partner (and likely also a substrate) of
JNK (218). Similarly, components of the canonicalWnt pathways,
including -catenin itself, can also become substrates of JNK
(270). JNK can also cross-regulate the Hippo/LATS pathway at
certain points, such as its phosphorylation of the coactivator
YAP1 (246, 286). Furthermore, JNK also regulates the synaptic
functions and learning processes of adult neurons through its sub-
strates PSD-95 and GluR2/GluR4, respectively (287, 288). Recent
research into the interactome of JNK has uncoveredmany further
potential targets of JNKpathways, including components of cyclic
AMP (cAMP)-dependent signaling (e.g., PDE4B, AKAP6), more
members of the canonical Wnt pathway (APC2), and Akt/PKB
signaling (INPP5F/SAC2), as well as the TNF- receptor complex
(RIPK2) and the JNK pathway itself (MEKK1, MLK2) (80). To-
gether, these studies highlight the possibilities for complex signal-
ing cross talk and feedback mediated by JNK-dependent phos-
phorylation of its substrates.
Molecular-Level Regulation of JNK Substrates: Looking into
the Black Box
The majority of JNK target sites, like the sites targeted by other
Ser/Thr kinases (and to a lesser extent, Tyr kinases), are located in
intrinsically disordered protein segments (289). The remaining
phospho-sites are mostly presumed to be within flexible loops
protruding from otherwise-rigidly folded domains. As a conse-
quence, JNK-mediated phosphorylation would rarely be expected
to have an effect on the conformation of its targeted proteins.
Instead, phosphorylation typically affects target protein function
by either creating or disrupting protein-protein interactions. In
this regard, the “loose” target site consensus for JNK-mediated
phosphorylation is significant; it enables the control of a diverse
set of protein-protein interactions, because the simple target site
requirement is compatible with a large pool of different linear
motifs. These kinase-controlled linear motifs can be considered
either positive or negative phospho-switches (290, 291); these
switches are considered in relation to JNK-dependent changes in
substrate proteins in the later subsections of this review.
Although some JNK-targeted linear motifs require only a single
site to be phosphorylated, it is common to find additional phos-
phorylation sites nearby that synergistically promote the same
protein-protein interaction (potentially because the binding en-
ergies for the individual phosphate groups are relatively modest).
Multisite phosphorylation also tends to result in a more robust
and switch-like behavior (292), and several kinase families effec-
tively drive efficient multisite phosphorylation events. Thus,
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“slave” kinases typically require priming by a “master” kinase, but
they may also be primed by sites that they themselves phosphor-
ylate, resulting in a chain reaction of phosphorylation events for
the same substrate.
Two major families of “slave” kinases have been identified for
the JNKs: the GSK3 and the CK1 families. The GSK3 family
(GSK3 and GSK3) represents the single most important part-
ner and modulator of JNK systems (293). GSK3s can recognize
substrates primed by the phosphorylation of Ser/Thr site 4 amino
acids downstream of their own targeted phospho-sites (294). Al-
thoughGSK3 does not strictly require their targeted amino acid to
be followed by a Pro, its optimal targeted phosphorylation se-
quence is still [S/T]-P, allowing it to replace JNK-mediated phos-
phorylation of appropriate sites. GSK3 is commonly needed for
the efficient phosphorylation of most phosphodegrons (Fig. 6A).
The CK1 kinase family (casein kinase 1 enzymes CK11, CK12,
CK1	, and CK1ε) contains additional well-established accom-
plices of JNK. CK1 kinases recognize Ser/Thr (with Ser preferred)
if they are preceded by an already-phosphorylated Ser/Thr amino
acid 3 amino acids upstream of the CK1 target site. The best-
known example for JNK-drivenmultisite CK1 phosphorylation is
the transcription factor NFAT4 (Fig. 6B). Since CK1 requires an
upstream priming site, it can processively phosphorylate sub-
strates in an N-to-C direction with 3-amino-acid spacing, unlike
GSK3, which senses downstream priming events and proceeds in
an opposing C-to-N direction, with 4-amino-acid spacing. In
summary, these examples highlight that single-site phosphoryla-
tion by JNKs needs to be examined in the context of the activity to
prime the actions of its “slave” kinases.
The same protein may also contain multiple, JNK phosphory-
lation site-regulated motifs, each pertaining to a different regula-
tory mechanism. A well-known example is c-Jun itself (Fig. 7A).
Detailed analysis of phosphorylation sites suggests that they form
part of at least three separate linear motifs in the intrinsically dis-
ordered Jun proteins. The two N-terminal motifs (each contain-
ing two conserved phosphorylation sites), located near the
NFAT4-type JNKdockingmotif, are implicated in transactivation
by recruiting yet-unidentified coactivators, histone acetyltrans-
ferases, or generic transcription factors (295–298). The third mo-
tif, positioned several hundreds of amino acids away from the
docking motif, also contains two JNK target sites, where the latter
is a phospho-degron controlling ubiquitinylation-dependent deg-
radation of Jun proteins (299). The latter motif also cooperates
with GSK3 to provide double-phosphorylated motifs for the
FBW7 ubiquitin ligase. Additionally, the latter motif can also be
primed by other protein kinases (such as CK2) and provide a basal
level of protein turnover in the absence of JNK stimulation (300).
Due to the lack of strict spatial constraints, it is possible that the
phosphorylation of different target sites is directed by a single JNK
recruitmentmotif.However, the positioning of target sites relative
to the docking site likely has a profound impact on the extent of
JNK control: sites that are in a near-optimal range from the dock-
ing point (10 to 50 amino acids downstream) are expected to be
phosphorylated to a much higher extent and at a lower threshold
than sites that are located further away or in an otherwise-steri-
cally disfavored position, such as upstream of the D-motif (201).
These ideas regarding the spatial constraints for phosphoryla-
tion thus explain why JNK pathway activation can increase
c-Jun levels (via Jun gene autoinduction due to proximal, N-
terminal Jun protein phosphorylation) but not attenuate c-Jun
levels, observed only following sustained JNK activity (partly
due to the phosphorylation of the distant C-terminal sites in
Jun) (301) (Fig. 7B and C).
JNK Phospho-Switches Negatively Regulating Protein-
Protein or Intramolecular Interactions
Protein phosphorylation events may disable a particular inter- or
intramolecular interaction, thus acting as negative phospho-
switches. The addition of a phosphate to a Ser or Thr side chain
may make the motif incompatible with partner domain binding
due to either direct steric/size effects, electrostatic conflicts if the
unmodified amino acid is coordinated by negatively charged side
chains, or intrachain competition with the disruption/formation
of salt bridges. Several notable examples of JNK substrates have
been described for JNK-mediated phosphorylation negatively
controlling various protein-protein interactions.
A simple example of a JNK-driven negative phospho-switch is
the phosphorylation of the dynein light chain (DLC)-bindingmo-
tifs of the BH3-only apoptosis regulator protein Bim. Both Bim
and its close relative Bmf harbor a canonical TQT DLC-binding
motif (302), in which the second Thr (underlined) is followed by
a Pro, so that its phosphorylation by JNKs or other Pro-directed
Ser/Thr kinases prevents its interaction with DLC (Fig. 8A). The
ensuing release of Bim from its transport adaptor-bound com-
plexes likely sensitizes cells to proapoptotic stimuli (302). Another
important proapoptotic protein, BAD, can also be modified by
JNK (303), leading to release of BAD from 14-3-3 protein-bound
complexes. The mechanism of this release probably differs, be-
cause within the targeted sequence (SPFRGRSRSA), the JNK-tar-
geted phosphorylation site (Ser [underlined in the sequence]) is
FIG 6 Cooperation between JNK and other kinases in substrate phosphory-
lation. (A) Phosphorylation by JNK can serve as a priming site for GSK3 en-
zymes in several substrates. The latter targets the site 4 amino acids upstreamof
the priming site, with a preference for proteins where the upstream Ser/Thr is
also followed by a small amino acid, such as Pro. The double-phosphorylated
region can often act as a phosphodegron, as in the case of c-Jun, where the
motif is subsequently recognized by the cullin/F-box ubiquitin ligase FBW7.
(B) Sites phosphorylated by JNK can also be recognized by casein kinase 1
(CK1). These enzymes phosphorylate Ser/Thr residues 3 amino acids down-
stream of the original phosphorylation site, with few sequence constraints.
Like most other kinases reliant on substrate priming, CK1 can also recognize
sites phosphorylated by itself. In the case of NFAT4, this leads to a chain of
phosphorylation events initiated by JNK. Multisite phosphorylation of this
so-called SRR1 (serine-rich region 1) motif then leads to cytoplasmic anchor-
ing of NFAT4, although its precise binding partners are unknown.
Zeke et al.
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located near two Arg residues (in bold), constituting an Akt1-
dependent phosphorylation site (the final Ser is shown in bold and
italics). Akt1-dependent phosphorylation events are absolutely
required for 14-3-3 binding and sequestration of BAD; interfer-
ence with either event would allow the release of BAD and trigger
apoptosis (304). Several members of the Bcl2 family may also be
JNK substrates that are subjected to negative regulation by JNKs,
but their phosphorylation sites are often poorly conserved and
evolutionarily do not correspond to each other. In the case of Bcl2,
multisite phosphorylation (at least on Ser70 and Ser87) inhibits its
binding to the apoptosis and autophagy regulator Beclin, thus
leading to autophagy activation (305, 306).
ManyNFAT proteins are also substrates of JNKs, counteracting
calcineurin and Ca2
 signaling (307–309). However, different
NFATs may be regulated at different sites and by different mech-
anisms. NFAT2 (NFATc1), for example, was found to be phos-
phorylated directly at its PxIxIT motif, which is responsible for
calcineurin recruitment (308). Although phosphorylation of this
site (APALESPRIEITSCL, in which the PxIxIT motif is indicated
in bold) does not result in an obvious steric clash with the surface
of calcineurin, it markedly decreases its affinity (possibly due to
intrachain effects). The resulting weakening of the association be-
tween calcineurin and NFAT2, thus acting as a negative phospho-
switch, would in turn lead to NFAT2 hyperphosphorylation by
other kinases and its relocalization to the cytoplasm (308).
Within the class of cytoskeletal proteins, the intermediate fila-
ment-forming protein cytokeratin-8 was among the earliest-de-
scribed JNK substrates (310); its Ser74 phosphorylation site lies in
the conserved, but disordered, head “domain” of this protein and
is critical for the assembly of higher-order filaments, in coopera-
tion with its partner, cytokeratin-18. Although the structural de-
tails are unknown, cytokeratin-8 Ser74 phosphorylation can also
be achieved downstream of ERK or p38 activation (311), but it is
implicated in the disassembly of filaments, possibly through aneg-
ative phospho-switch (312). Thus, simple negative phospho-
switches have the capacity to mediate the actions of JNKs across
multiple cellular compartments.
Phosphorylation can also elicit disruptive effects by more com-
plex, multistep mechanisms. JNK-mediated phosphorylation of
the nuclear receptor PPAR- severely inhibits its transactivation
potency via a complex negative switch (242). Specifically, the im-
mediate surroundings of the target phosphorylation site (IKVEP
ASPPYY) form a WW domain ligand (SPPxY motif correspond-
ing to the C terminus of this site), while also conforming to a
phosphorylation-induced SUMOylationmotif (IKxExxSP, corre-
sponding to the N terminus of this site). SUMOylation of the
motif by the Ubc9 SUMO-conjugating enzyme following phos-
phorylation renders this sequence sterically inaccessible for WW
domain-containing transcriptional regulators (including TAZ
and YAP) (313) (Fig. 8B). The importance of this switch region
FIG 7 JNK-dependent phosphorylation of c-Jun elicits diverse effects. (A) The three Jun proteins (c-Jun, JunB, and JunD) were the first JNK substrates to be
described and are still perhaps the best-known targets of the JNK pathways. The c-Jun protein can be phosphorylated at several sites by JNK; themost important
regulatory sites are located in three different linear motifs. Phosphorylation of the two transactivator motifs located directly next to the docking motif can elicit
transcriptional activation, probably due to phosphorylation-dependent recruitment of unknown effector proteins. This results in transcriptional activation of
genes containing a Jun (AP-1)-binding element on their promoters, including c-Jun itself. On the other hand, phosphorylation of a much more distant
phosphodegron motif in c-Jun, either by JNK alone or by cooperating with GSK3, represents an opposing regulatory mechanism. The latter provides a way for
negative regulation of c-Jun levels by JNK, the mechanism for which is interestingly absent in the oncogenic v-Jun. (B) Under low or transient JNK activity, the
c-Jun phospho-sites directly adjacent to the D-motif are the first to be phosphorylated, due to their favorable stereochemistry and strong coupling with the
docking site. This results in a sharp rise of c-Jun mRNA and protein levels, due to autoinduction of the c-Jun gene. (C) If JNK activity is high and/or sustained
over several hours, efficient phosphorylation of the distant C-terminal sites may also occur. The result will be the well-known attenuation of c-Jun levels due to
ubiquitinylation and proteasome-dependent degradation of phospho–AP-1 complexes.
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was highlighted by the observations of mutations at the Pro adja-
cent to the phosphorylated Ser in a severe, hereditary obesity syn-
drome (314). These observations reinforce the critical role of
this complex as a negative switch in regulating PPAR- activity
(315). Similarly, the phosphorylation of heat shock factor
HSF1 at Ser303 (part of an IKxExxSP motif) by several MAPKs,
including JNK, leads to SUMOylation (316–318). This subse-
quently inhibits their transactivation potency, although the ex-
act interaction partner disabled by steric effects in this case
remains unknown.
Not all JNK-dependent phosphorylation events control pro-
tein-protein binding events; the disruption of intramolecular in-
teractions following phosphorylation can also be an important
regulatory event for several proteins. In the case of the E3 ubiqui-
tin ligase ITCH, JNK-dependent phosphorylation can relieve the
autoinhibitory interactions between the array of WW domains
(responsible for substrate recruitment) and the catalytic HECT
domain (319). Indeed, ITCH autoinhibition is probably even
more complex, since one of the key phosphorylation sites control-
ling autoinhibition is part of a Pro-rich, basic, and highly con-
served linear motif (RPPRPSRPPPPTPRRP) near the N terminus
that belongs to neither theWWnor the HECT domain. The latter
motif could serve as an “autoligand” for the enzyme or its WW
domains only, perhaps “sandwiching” the rest of the protein in its
autoinhibited, self-associating state (Fig. 8C). Interestingly, nei-
ther the phosphorylation sites nor any other features of the motif
are found in related NEDD4-like E3 ubiquitin ligases, suggesting
that this autoinhibitory mechanism is unique to ITCH.
JNK Phospho-Switches Potentiating New Protein-Protein
Binding Events
For many substrates, JNK-mediated phosphorylation may di-
rectly establish new protein-protein interactions, i.e., acting as
positive phospho-switches. A large number of protein domains
have been described that bind to linear motifs containing phos-
pho-Ser or phospho-Thr residues, either in an obligatory fashion
or in a facultative fashion in which Asp or Glu can replace some of
the phosphorylated residues (320, 321). Unfortunately, the dedi-
cated interactors for relatively few JNK substrates have been iden-
tified. However, for several unrelated effector proteins involved in
protein degradation, transcriptional activity, cytoskeletal dynam-
ics, or other modifications, intriguing details of their selective re-
cruitment by special JNK target phospho-motifs have been re-
vealed.
Some of the best-explored effectors of JNK-dependent phos-
phorylation events, at least from a structural perspective, are the
E3 ubiquitin ligases, by which the ensuing interactions can drive
the proteolytic destruction of the JNK target. The E3 ligase subunit
FBW7 (also known as Archipelago or Cdc4) recognizes linearmo-
tifs with the sequence TPPxSP (or similar) in its substrates, where
FIG8 Negative phospho-switches and autoinhibitory switches driven by JNK. (A)A simple negative switch, illustrated by Bim. Phosphorylation of a dynein light
chain (DLC)-binding motif in the BH3-only apoptosis regulator protein Bim impedes its binding to DLC-DIC (dynein intermediate chain) complexes. This
shifts the equilibrium toward free Bimmolecules, eventually completely releasing them into the cytoplasm. (B) A complex negative switch occurring on PPAR.
The disordered N terminus of the peroxisome proliferator-activated receptor  contains a WW domain ligand and an overlapping PDSM (phosphorylation-
dependent SUMOylation motif). Phosphorylation by JNK can therefore elicit SUMOylation of PPAR, making its association with WW domain-containing
coactivators (such as YAP1) sterically impossible. Ubc9 is a SUMO-conjugating enzyme. (C) The autoinhibitory switch of the ITCH ubiquitin ligase. As typical
for the NEDD4 family of E3 ubiquitin ligases, ITCH is subject to autoinhibition. According to studies, the autoinhibitory interface of ITCH is complex, and the
C2 domain, linkers, and its WW domains all contribute to maintenance of the “closed” conformation. JNK-dependent phosphorylation of certain residues
located in the linker region interfere with the autoinhibitory interactions. This “opens up” the catalyticHECTdomain of the ITCHenzyme, allowing the E3 ligase
to recruit and ubiquitinylate its substrates.
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both Ser/Thr amino acids are phosphorylated (322). This dual
phosphorylation, following actions of JNKs and the auxiliary ki-
nase GSK3, results in K48-linked polyubiquitinylation and subse-
quent degradation of substrates by their recruitment into the pro-
teasome. Since FBW7-containing cullin/F-box enzymes are
dimeric, their optimal substrates either carry multiple phospho-
degrons or are also oligomeric (323). This helps explain earlier
observations that the levels of the Jun family transcription factors
are regulated by JNK in both a positive and a negativemanner, the
latter mediated by a C-terminal phosphodegron distinct from the
transactivator region. Interestingly, this phosphodegron is absent
from the oncogenic v-Jun protein (299), explaining v-Jun’s pro-
longed activation downstream of JNK activation. Within their N
termini, the proto-oncogene Myc-family proteins also carry an
FBW7phosphodegron that can be phosphorylated by JNK, result-
ing in ubiquitinylation and degradation (324) (Fig. 9B). More
recently, a similar phosphodegron was identified for the Bcl2-
family member Mcl1 (282, 325). This degradation of the antiapo-
ptotic Mcl1 provides another mechanism by which JNK can sen-
sitize cells to proapoptotic stimuli (281). Phosphorylation of the
PPM1J phosphatase at Ser92 (part of a potential FBW7-type phos-
phodegron, AVQSPPDTGR) can also profoundly reduce its activ-
ity in cells (71), albeit that the impact of JNK-mediated phosphor-
ylation on PPM1J ubiquitinylation and its half-life have not been
specifically studied. This putative phosphodegron of PPM1J is not
evident in the closely related PPM1Hphosphatase, suggesting dif-
ferential regulation of these phosphatases by JNKs which may, in
turn, dephosphorylate anddeactivate JNKs. Twophosphorylation
sites of the recently identified JNK substrate SMTL2 (a close rela-
tive of the actin-binding protein smoothelin) also lie in a con-
served motif resembling a near-optimal FBW7 phosphodegron
(PLVTPPQSPVS; phosphorylation sites are underlined). Al-
though the functions of SMTL2 require further exploration (69),
these examples provide interesting insights into proteins regu-
lated through the interplay of JNK-mediated phosphorylation and
their ensuing degradation.
Other ubiquitin ligases may also recognize JNK-phosphory-
lated linear motifs. Smurf1 and its relationships with the SMAD
transcription factors and Nur77 provide interesting examples.
[S/T]-P phosphorylation of SMADs by multiple kinases, includ-
ing the JNKs (326, 327), switches their interactionswith YAP/TAZ
transcription factor proteins toward binding to the NEDD4-like
E3 ubiquitin ligase Smurf1 (328). In this example, one of themul-
tiple WW domains of Smurf1 mediating this interaction requires
FIG 9 Positive phospho-switches and allosteric switches controlled by JNK. (A) A simple positive switch acting on Elk1. Phosphorylation of the ETS transcrip-
tion factor Elk1 by JNK1 (or ERK1/2) onmultiple sites at its transactivation region creates a new linearmotif. This protein-protein interactionmotif binds to the
histone acetyltransferase CBP/P300, likely through its second TAZ zinc finger domain. Thus, Elk1 can recruit chromatin-modifying enzymes that enhance
transcription of its target genes. (B) A complex positive switch exemplified by phosphodegron systems. Several substrates of JNK, such as c-Myc, contain
phosphodegron motifs. Multistep phosphorylation of such a motif (using GSK3) results in the recruitment of an E3 ubiquitin ligase complex containing the
recognition subunit FBW7. Subsequent ubiquitinylationwill then generate another newprotein-protein interaction, this timewith the lid of the proteasome. The
result is usually the degradation of the ubiquitinylated protein, which in this sense is an inhibitory outcome (despite all protein-protein interactions being
positive). (C) An allosteric switch on RXR elicited by JNK-dependent phosphorylation of a regulatory loop. The retinoid X receptor  is an allosterically
sensitive protein which only recruits the coactivator NCoA2 in its ligand (11-cis-retinoic acid [11-CRA])-bound state. The JNK-phosphorylated loop is directly
adjacent to the ligand-binding pocket, and all available evidence suggests that it will bind back to the pocket whenmodified. The consequential distortion of the
ligand-binding site would not only elicit release of 11-CRA, but also its coactivators, thus shutting down RXR-dependent transcription.
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the canonical PPxY motif, but the other recognizes phosphory-
lated motifs instead and it binds in a reverse orientation, thus
promoting interaction and the subsequent degradation of
SMAD1 (328). Similarly, the orphannuclear receptorNur77, after
its multisite phosphorylation by JNKs, can be recognized as a sub-
strate of Smurf1, albeit the structural details are not yet clear (329).
While numerous phosphodegrons have been identified with
links to specific enzymes driving these changes, the exact identities
of many of the cytosolic or nuclear enzymes involved are still not
clear in many cases. Among nuclear substrates, phosphorylation-
dependent degradation has been described for the retinoid recep-
tor RAR and the Jun partner protein JDP2. The RAR site is not
conserved in the related RAR or RXR proteins (243), emphasiz-
ing differences in JNK-mediated control of these proteins. How-
ever, the lack of similarity with other known phosphodegronmo-
tifs suggests the involvement of hitherto-unidentified enzymes for
RAR degradation. Similarly, the Jun partner protein JDP2 is tar-
geted for proteasomal degradation by unspecified ubiquitin li-
gases after its phosphorylation at Thr148 (330). A phosphoryla-
tion site homologous to Thr148 of JDP2 is also found on the
related ATF3 protein, but ATF3 levels appear to be controlled by
JNK in a much weaker manner than is JDP2 (330).
In the cytoplasm, JNK-dependent phosphorylation of the mi-
crotubule regulatory protein Stathmin-2 (also known as SCG10)
at Ser62 and Ser73 can also induce proteasome-dependent degra-
dation of the protein, although the involvement of ubiquitin li-
gases has not been studied (331). The phosphorylation of Ser69
within the alternative N terminus of the BH3-only protein Bim
(distinct from theThr116DLC-bindingmodulatory site discussed
above) can trigger ubiquitinylation, but the molecular details of
the degradation events require further evaluation (332). Despite
the numerous well-characterized examples, it is important to note
that not all phosphorylation sites that affect ubiquitinylation are
degrons. The phosphorylation of the regulatory C terminus of
S6K1 (p70-RSK) also promotes its ubiquitinylation and degrada-
tion (333). However, this unusual target region (SPRRFIGSPRTP
VSPVKFSP; phosphorylation sites are underlined) possibly elicits
its effects in an indirect way, as C-terminally truncated proteins
were more unstable. Thus, some JNK-mediated phosphorylation
events may also control protein turnover in a more indirect man-
ner, not by recruiting ubiquitin ligases directly but by disrupting
complexes that would mask the true degrons.
Ubiquitin ligases are not the only major effectors of JNK phos-
phorylation. Numerous substrates have been described (e.g.,
-APP, Tau, c-Jun) in which phosphorylation triggers an interac-
tion with the peptidyl-prolyl cis-trans isomerase Pin1 (132, 334–
336). The importance of Pin1-mediated Pro-peptide bond
isomerization lies in its roles in protein folding and because cer-
tain linear motifs require particular Pro configurations (i.e., Pro
positioned with a turn will likely be of a cis conformation, but a
Pro in other contexts will be of a trans conformation) (337). Pin1
contains a substrate-recruiting WW domain that requires barely
more than a Ser-Pro or Thr-Pro (SP or TP) site in which the
serine/threonine amino acid is phosphorylated (338) and a con-
served catalytic domain that shows a preference toward isomeriz-
ing phospho-Ser-Pro or phospho-Thr-Pro (pSP/pTP) bonds
(339). One should note, however, that the catalytic domain of
Pin1 is incapable of accessing a pSP/pTPmotif that is bound to the
WWdomain (in a trans conformation); only other, adjacent pSP/
pTPmotifs can be targeted for cis-trans isomerization. The gener-
ation of cis- pSP/pTP stereoisomers is significant: protein kinases
primarily phosphorylate trans-SP/TP sites only, andmany known
effectors (including the previously mentioned FBW7 ubiquitin
ligase or the PP2A phosphatase) can only access trans-pSP/pTP
sites. Dedicated binding partners requiring cis-pSP/pTP sites also
do exist (340) but still await identification for most JNK sub-
strates.
JNK-mediated phosphorylation can directly induce protein-
protein interactions, as exemplified by their regulation of tran-
scription factor proteins. Despite some of the best-known JNK
substrates beingwell-established transcription factors, our knowl-
edge of their specific interacting partners and how these interac-
tions are influenced by phosphorylation is still remarkably poor.
One of the structurally clearest cases is provided by the ETS tran-
scription factor family member Elk1, which can be phosphory-
lated at the same sites by either ERK2 or JNKs. In Elk1, the phos-
phorylation of a long (50 amino acids) and presumably fully
disordered transactivator region is required for binding to p300/
CBP histone acetyltransferases that are essential for enhanced
transcriptional activity. Elk1 lacks the classical transactivator mo-
tifs (such as the 9-amino-acid TAD motif) that could enable a
strong, constitutive interaction with the TAZ, KIX, or IBID do-
mains of p300/CBPs (341). Instead, it appears to rely on phos-
phorylatable linear motifs (e.g., the highly conserved SIHFWSS
LSP) segment, incorporating the Ser383 site ([underlined], could
theoretically be a 9-amino-acid TAD-like helical motif) that bind
to the same domains in a regulated manner (342) (Fig. 9A). The
same sites and motifs are also seen in the related Elk3 (originally
known as Net) and Elk4 proteins, but their corresponding D-mo-
tifs may preferentially bind ERK2 and p38 rather than JNK
(343). More recently, members of the NuA4 histone acetyltrans-
ferase complex, including TRRAP and TIP60, were also suggested
to be preferred partners and effectors of phosphorylated Elk1
(344), so p300/CBPsmight not be the only effectors andmight not
even be the main partners of phospho-Elk1.
c-Jun/JunD and ATF2 transcription factor proteins are also
well-known JNK substrates. In the case of the ATF2 family pro-
teins, phosphorylation of an intrinsically disordered transactiva-
tor motif on two adjacent positions (Thr69 and Thr71 in human
ATF2) is a prerequisite for the activation of promoters to which
they bind (345). Although these phosphorylation events would
directly trigger some protein-protein interactions, their binding
partners are still unclear, as experimental data on the role of p300/
CBP and others remain controversial (346). The case of Jun family
transcription factors is slightly more complex: these proteins pos-
sess an N-terminal transactivator motif with two well-conserved
phosphorylation sites (Ser63 and Ser73 of c-Jun), in addition to
the motif also found in the ATF2 family (Thr91 and Thr93 in
human c-Jun). Therefore, it is possible that these two motifs re-
cruit different partners simultaneously to phosphorylated Jun
proteins. However, none of the proposed effectors (p300/CBP,
TFIID, TCF4, MBD3) have been well characterized as partners
(295–298). The same can be said for the AP-1 partner, the Leu
zipper transcription factor Nrl, which is required specifically for
retinal development. The STPYSSVPPSPTFS motif surrounding
Ser50 (underlined; the main JNK-mediated phosphorylation site
in Nrl) is highly conserved among the Maf family transcription
factors and required for efficient transcription of Nrl target genes;
it is still unclear if this effect is mediated by TIP60 histone acetyl-
transferase or not, since JNK activity and TIP60 binding to Nrl-
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containing promoters did not correlate in vivo (347). Thus, these
proposed partnerships require further evaluation.
JNK also targets diverse cytoskeletal proteins involved in adhe-
sion, cell migration, and the cytoplasmic trafficking of proteins,
organelles, and vesicles. Unfortunately, the mechanistic insights
into these important processes remain largely limited. One of the
better-characterized substrates is the focal adhesion protein pax-
illin. Although paxillin has been implicated as an ERK2-depen-
dent target, it can also be phosphorylated (at least on Ser 178) by
JNK (268, 269). Paxillin displays an intriguing interplay between
Ser/Thr and Tyr phosphorylation. Across all proteins, most of the
known Tyr phosphorylation sites are flanked N-terminally by one
or more negatively charged amino acids (Glu/Asp) because these
are needed for their recognition by most Tyr kinases (348, 349).
Intriguingly, two major tyrosine phosphorylation sites (shown in
bold) in paxillin (Tyr88, SSPVYGSS, and Tyr181, LSPLYGVPE)
lack these charged positions. Instead, they contain SP sites (under-
lined), allowing MAPK-dependent phosphorylation events to
provide the necessary negative charges. Thus, ERK2 or JNKs can
promote tyrosine phosphorylation and subsequent Crk and/or
Src binding of paxillin, which leads to stronger focal adhesion
kinase binding, Src kinase activation, and greater tyrosine phos-
phorylation (350). Thus, the example of paxillin demonstrates
how JNK-dependent phosphorylation can potentially expand the
repertoire of Tyr kinase protein targets.
Lesser-Understood JNK-Dependent Phospho-Switches
Although the preceding examples illustrate how JNK-mediated
phosphorylation can exert actions as either positive or negative
phospho-switches, there are numerous examples in which this
delineation of effects is less understood. For example, transcrip-
tion factor complexes such as the YAP/TAZproteins togetherwith
p73 and p63 proteins (relatives of the better-known p53 tumor
suppressor protein) constitute a critical transcriptional complex
in which both protein partners can be regulated by JNKs. Specif-
ically, the coactivator protein YAP1 is also subject to multisite
phosphorylation that can be considered a complex phospho-
switch. At least four sites (of which two are highly conserved) were
identified as JNK targets in response to genotoxic stress (351), and
all play a role in transactivation by YAP1, albeit by differentmech-
anisms. Ser128 (underlined in the following sequence; it is also
conserved in TAZ) lies near the TEAD-binding region of YAP1,
directly inside one of the two LATS-phosphorylated 14-3-3 bind-
ing sites (HVRAHSSP). This endows JNK with the potential to
counteract Hippo/LATS kinases, setting YAP1 free to interact
with TEAD transcription factors (351). On the other hand,
Thr412 (underlined in the following sequence) is part of a
conserved, long sequence motif (YSVPRTPDDFLNSVDEMDTG
D) lying in a disordered C-terminal region important for
transactivation (352). It shows some sequence similarity to the
transactivator motifs of p53 and other 9-amino-acid TAD motifs
(recruiting TAF9 or p300/CBP); however, its precise binding
partners have not been established.
The transcription factor p73 has at least seven potential JNK
phosphorylation sites, of which several are highly conserved and
also found in its close paralog, p63. Except for the C-terminal
Thr482 (TPPPPY motif), which potentially modulates the bind-
ing of WW domain-containing partners (e.g., YAP1, WWOX,
ITCH, HECW2), the exact functions of the other sites are un-
known. Experiments suggest that these motifs (such as the N-ter-
minal SPY motifs) are important for transactivation of p73-de-
pendent genes as well as stabilization of the p73 protein by
protecting it from ubiquitinylation (239).
JNK can also regulate translation of specific mRNA transcripts
through targeting the RNA-binding protein hnRNP-K (256). Of
the three phosphorylation sites identified in human hnRNP-K,
two (Ser216 and Ser284) are conserved in most other vertebrate
species. Ser216 lies immediately after the second Ku homology
(KH) domain, as part of its conserved extension. It is probably
required for its interaction with the ribosomes, essential for the
translation of associated mRNA in developing neurons, in order
to support axon outgrowth (257).
Several cytoskeletal proteins show conserved motifs surround-
ing their JNK phosphorylation sites. In most cases, it is unclear
whether the modification induces a new interaction or abolishes
existing ones. Some of the most intriguing examples encompass
important microtubule-associated proteins. The microtubule-as-
sociated, intrinsically disordered MAP2 and Tau proteins are
among the earliest discovered MAPK substrates and are exten-
sivelymodified in vivoby JNKat several conserved sites (180).One
key region is the segment immediately preceding themicrotubule-
binding repeats in these proteins. ForMAP2, the phosphorylation
of a conserved “perimicrotubular” motif (TPGTPGTPS, contain-
ing Thr1619, Thr1622, and Thr1625 [underlined] of MAP2) in-
creased microtubule binding, although the molecular details of
this regulation were not fully explored (353). The phosphoryla-
tion of the neighboring, well-conserved KKVAIIRTPPKSPA mo-
tif has been better documented in Tau than inMAP2. This MAP2
region is similar to an FBW7 phosphodegron of Tau (Thr231 and
Ser235 [underlined in the above sequence]), which is modified in
cooperationwithGSK3. Although phosphorylationwas originally
reported to inhibit the microtubule-binding ability of Tau, more
recent research suggests thatmodification of these sitesmaynot be
sufficient to induce Tau dissociation from microtubules (354,
355). The phosphorylation of the latter motif may still contribute
to neurotoxicity and filament forming when Tau is released from
microtubules in Alzheimer’s disease (355). These mechanistic
links thus can help inform possible approaches to intervene in
neurodegenerative diseases.
Many other microtubule-binding proteins are also JNK sub-
strates, including the X-linked lissencephaly protein DCX (dou-
blecortin-X). DCX is a critical regulator of neurogenesis and post-
mitotic neuroblast migration, capable of binding to JNK directly
and also containing numerous JNK phosphorylation sites (261,
262). Interestingly, most of the sites located N-terminally and C-
terminally from the microtubule-binding tandem doublecortin
domains are also conserved in the closely related doublecortin-
like kinases 1 and 2 (DCLK1 and DCLK2), but not in the more-
divergent DCLK3. Currently, the most plausible explanation is
that these motifs have a role in regulating microtubule-actin
cross-linking through binding to unidentified effectors (especially
by Ser297 phosphorylation, which is part of the highly conserved
AKSPGPMRRSKSPA motif in the disordered C-terminal tail of
DCX) (356). Furthermore, the JNK-mediated phosphorylation of
WDR62, a microtubule-binding protein and established JNK in-
teractor, regulates its subcellular localization (213, 357). The crit-
ical Thr1053 phospho-site, together with its surroundings (PQTP
EQEKFLRHHFELTLT), is highly conserved in vertebrates, in
comparison to adjacent regions, thus hinting at a true linearmotif.
The sequence conservation for WDR62 with the related protein
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MABP1 (MAPK-binding protein 1) extends to the JNK-docking
motif (80), but whether the phospho-motif directly associates
with the microtubules, or binds to some other protein, is not yet
known.
For the synaptic scaffolding protein PSD-95 (also known as
Disks large homolog 4 [DLG4]), its phosphorylation by JNK on
Ser295, located in the flexible linker between the second and third
PDZ domains, enhanced its synaptic localization (287). Again,
this site forms part of a larger motif (TPTSPRRYSPVAKDLLGE
EDI) that is very conserved, unlike other parts of the linker, and is
also encountered in several paralogs (DLG1, DLG2, and DLG3).
Despite these observations, the molecular details of the functions
of this motif remain completely unknown (287). The highly con-
served cytoplasmic tail of the AMPA-type glutamate receptor
GluR4 and the long isoform of GluR2 are also JNK substrates (at
Thr875 and Thr874 of the human proteins) (288). These receptor
ion channels are implicated in learning processes, and the phar-
macological blockade of JNK pathways impaired the ability of
these channels to be reincorporated into the membrane after in-
ternalization. The trafficking complexes mediating this process
remain unidentified, but JIP1 remains a candidate (288). Lastly,
the fully disordered actin-binding protein MARCSKL1 is another
important cytoskeletal JNK substrate. In this case, concomitant
phosphorylation of three sites (corresponding to Ser120, Thr148,
and Thr178 in human MARCKSL1) enhanced the F-actin-bind-
ing capacity (266). Two of the three sites are poorly conserved, but
Ser120 lies in a region (SSPTEEEQ) also evident in its fish or-
thologs. As none of these phosphorylation sites is situated in the
central actin-bindingmotif, the underlying mechanism of regula-
tion by phosphorylation cannot be easily inferred. However, the
interaction of the central motif toward actin may be strengthened
by the presence of downstream phosphorylated motifs, because
F-actin-binding linear motifs may contact multiple surfaces of
actin molecules. This role further emphasizes the critical impor-
tance of JNK-mediated phospho-switches in the cytosol, beyond
stress-induced signaling events.
Phosphorylation-Induced Conformational Changes in
Folded Domains
In contrast to the numerous reported JNK-directed phospho-
switches acting on linear motifs, relatively few JNK-mediated
phosphorylation events are known to elicit their effect through
classical allostery. In this case, phosphorylation of a relatively flex-
ible and accessible SP/TP site would direct its binding to a directly
adjacent, folded domain, leading to conformational changes in
the domain structure. Such effects were described for the retinoid
X receptor RXR (245). Phosphorylation of a mobile loop pro-
truding from the ligand-binding domain of RXR leads to its
direct inhibition by JNK. Since the phosphorylatable amino acid
(Ser260) is located in close proximity to the ligand-binding pocket
(but far from the coactivator/corepressor recruitment site), the
phosphorylation event probably directly modulates ligand (11-cis
retinoic acid) binding (Fig. 9C). The endothelial nitric oxide syn-
thase (eNOS) may provide another case of JNK-mediated alloste-
ric regulation. The phosphorylation of eNOS at Ser114 (lying on a
loop on the heme domain, directly facing its catalytic site) poten-
tiated its activity (358). Multiple 14-3-3 proteins (such as 14-3-3
or 14-3-3) were also described as being phosphorylated by JNK
(277, 278, 359, 360). Their case is quite unusual, as the phosphor-
ylation site lies in a structural domain, on a short loop connecting
two -helices. Surprisingly, this Ser-Pro amino acid pair (S184-
P185 in the human 14-3-3protein) could theoretically fit into the
catalytic site of JNK without a clash, allowing phosphorylation of
a relatively fixed side chain protruding from a folded domain. The
modification of this site has important consequences, as it can
potentially distort the relative positioning of the underlying heli-
ces, thus dismantling the ligand-binding groove of 14-3-3 pro-
teins. This allows an allosteric, negative regulation ofmany 14-3-3
ligands controlled by kinases like PKB/Akt (270), emphasizing
that these changes likely have broader impact.
Complex Effects of JNK on Its Substrates
JNKphosphorylation can also influence nucleo-cytoplasmic shut-
tling events, but the exact molecular mechanisms for many JNK
substrates are not well understood at a molecular level. The
well-known JNK substrate NFAT4 is primarily regulated by its
phosphorylation-regulated localization (307). In this case, JNK
“primes” the so-called SRR1 (Ser-rich region 1) motif of NFAT4
for sequential phosphorylation by casein kinase 1 (CK1) (307,
361). The distance (100 amino acids) between the SRR1 and
nuclear localization sequence (NLS) motif within the disordered
N terminus of NFAT makes a direct interaction between the two
unlikely (362). Therefore, it is probable that the phosphorylated
SRR1 motif binds to cytoplasmic proteins that anchor NFAT4 in
the cytoplasm (thus inhibiting its transcriptional activity) until its
subsequent dephosphorylation by calcineurin. JNK-dependent
phosphorylation of the androgen receptor likewise inhibited its
nuclear localization (240). But in this case, the phosphorylation
site within the linker between the DNA binding and ligand bind-
ing domains is located close to the NLS motif, making direct in-
tramolecular effects more likely (363). The glucocorticoid recep-
tor is also phosphorylated by JNK on Ser226; this inhibitory
phosphorylation was proposed to act through an enhanced nu-
clear export of receptors (241). Since the amino acids surrounding
this site do not correspond to the better-known nuclear export
signals (NES), it is possible that the export effect is secondary to
other changes. Thus, the impact on protein nuclear localization
and/or shuttling can result from different mechanisms impacting
cytoplasmic retention, nuclear translocation or nuclear export.
The protection fromubiquitinylation and/or proteolytic degra-
dation (protein stabilization) frequently can also be a result of
multistep regulation. Currently, very few degron motifs are
known that would be directly inhibited by phosphorylation; how-
ever, the protection from degradation can be achieved by the in-
clusion in vivo of highly unstable, degron-containing proteins into
multiprotein complexes, in which their degron motif is masked.
Although the basic helix-loop-helix (bHLH) transcription factor
Twist1 was described as being stabilized by JNK phosphorylation
(233), the targeted site (Ser68, which is also conserved in Twist2)
is located within a classic, potentially bipartite NLS motif, only 4
amino acids N-terminal of the major -importin-binding site
(364). Phosphorylation within this region is known to enhance
nuclear import of affected proteins (365). Therefore, Ser68 phos-
phorylation may control the nuclear translocation of Twist1
(which is known to be potentiated by epidermal growth factor
stimulation), to which Twist1 stabilization might be a secondary
effect (366). In the case of the bHLH transcription factor Hes1,
JNK-dependent phosphorylation of Ser263 within its flexible C
terminus resulted in its stabilization (232). While the phosphory-
lation site itself is not strictly conserved in all vertebrates, the di-
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rectly adjacent (extended WRPW-type) Groucho corepressor-
binding motif is always preserved (367). Due to their close
proximity (with only 3 amino acids lying between the twomotifs),
it may be that phosphorylationmodulates Groucho binding, pos-
sibly providing stabilization as a secondary phenomenon. JNK
could also phosphorylate the Zn finger transcription factor Sp1 on
at least two distinct sites (Ser278 and Ser739 of human Sp1) in its
extensive N- and C-terminal disordered regions. The modifica-
tion of both, but especially the C-terminal site, provided a pro-
found stabilization effect, thus increasing the cellular Sp1 concen-
tration by prolonging its half-life (234). Examination of the Sp1
sequence reveals that both sites lie in close proximity to potential
-TRCP E3 ubiquitin ligase-recruiting phosphodegron motifs (S
SGSQES andDSGAGSEG, with the C-terminal motif being a bet-
ter match) (368). Phosphorylation of these -TRCP phosphode-
grons may potentially rely on autonomous GSK3 activity (due to
Glu residues positioned downstream).However, nearby JNK-me-
diated phosphorylation events may inhibit the function of these
phosphodegrons if they generate new protein-protein interac-
tions that compete with GSK3 and/or -TRCP recruitment.
JNK-Modulated Adaptors, Scaffolds, and Other Proteins
JNK-mediated phosphorylation can also regulate critically impor-
tant adaptor proteins. The insulin receptor substrate (IRS) family
of docking proteins also carry a conserved JIP1-type JNK docking
motif. The JNK-dependent phosphorylation of IRS1 and IRS2
proteins has been examined in a number of studies (273, 274,
369). The best-documented target sites (human IRS1 Ser312 and
human IRS2Thr350) lie close to a conserved 14-3-3 protein-bind-
ing motif (RSRTESITATSPAS and RSRTDSLAATPPAA;
boldface residues conform to the 14-3-3 binding consensus).
Although these JNK target sites are not identical, IRS2 Thr350
could assist GSK3-directed phosphorylation of the 14-3-3-
binding motif. However, the extensive disordered C termini of
both IRS1 and IRS2 contain a large number of better conserved
SP/TP sites, and it is likely that JNK can phosphorylate more
than just one of them. For example, in IRS2, another site was
identified more recently (Ser491 in human IRS2, within the
conserved motif SASASGSPSDPGFMS, also found in IRS1),
where JNK also provides a priming site for GSK3 (274).
However, the function of the latter motif is also obscure. That
JNK-dependent phosphorylation of IRS1 and IRS2 leads to a
strong inhibition of its tyrosine phosphorylation during insulin
stimulation (273) suggests a critical role for JNKs in the
development of insulin resistance (reviewed in reference 370).
The role of JNK-dependent phosphorylation is even less clear
formicrotubule-associated transport adaptors, which are not only
critical for trafficking of vesicles but also involved in JNK pathway
regulation. Despite extensive research, little is known of the func-
tional consequences of JIP1 phosphorylation. JNK can phosphor-
ylate JIP1 at over a dozen different sites, most of them lying within
its disordered N terminus or possible flexible loops (371). With
the exception of a single site (Thr448), none of these is conserved
in JIP2, although the JNK-docking motif itself is almost identical;
that JIP2 also harbors the same, JNK-specific motif as JIP1 casts
doubts on JIP2’s possible links with p38 rather than JNK (372).
Known regulatory sites of JIP1 (Thr103, located in the second
acidic motif, and Ser421, in the auxiliary cargo-binding domain)
are not found in JIP2. Thus, it is possible that despite their redun-
dant function in kinesin-dependent transport, JIP1 and JIP2 are
regulated differently by JNK. It can be assumed that one role of the
phosphorylation is to regulate JIP1/2-cargo or JIP1/2-kinesin
linkage or both in an indirect manner. Although nonvertebrate
animals do not contain JNK-docking motifs in their JIP1/2 pro-
teins, these proteins are essential for vesicular transport in Dro-
sophila, hinting at a JIP1/2 trafficking mechanism which is less
strictly coupled to JNK but also not completely independent from
it (373).
JIP3 and JIP4 (previously known as JLP or SPAG9) constitute a
separate protein family, although they share a name with the un-
related JIP1/2 family (372). The sequence similarity of the C-ter-
minal halves of JIP3 and JIP4 to the Rho-GAP domains of several
ARHGAP proteins suggests that they might possess a GTPase ac-
tivator ability toward Rho family small G-proteins (such as Rac1
or Cdc42). In addition, they are also implicated to be critical reg-
ulators of kinesin-dependent vesicular transport, binding the
small G-protein Arf and being members of the same transport
complex that incorporates JIP1/2 (128, 374–376). JIP4 has been
linked more strongly with p38 pathway activation (377). While
reports of JIP3 interaction with the MAP3K ASK1 require further
evaluation, JIP3 appears to be a genuine JNK substrate (105). Sev-
eral phosphorylation sites have been described on JIP3, with
Thr276 (within the motif GTKSNTPTSS) also being conserved in
JIP4. Interestingly, many of the SP/TP sites on JIP3 are incorpo-
rated into conserved “islands” of an otherwise-largely unstruc-
tured N terminus of JIP3/4, suggestive of multiple, JNK-regulated
linear motifs. Since the JNK pathway is activated by several GTP-
bound small G-proteins (through MLK/DLK kinases), feedback
mechanisms through GTPase regulator proteins are plausible.
However, the lack of detailed structural and functional studies
continues to hamper our understanding of JIP3 and JIP4.
Lastly, JNK can bind and phosphorylate the mitochondrial
outer membrane coiled-coil protein Sab (or SH3BP5) (378). We
know very little of the physiological role of Sab Ser330 phosphor-
ylation, but the extensive conservation of sequence over a long
stretch (PRSECSGASSPECEVERGDRAEGAE) surrounding the
phosphorylation site across all vertebrates suggests a likely regu-
latory role, which is supported by recent studies implicating the
Sab/JNK relationship in initiating regulatory control over in-
tramitochondrial Src actions and reactive oxygen species produc-
tion (379).
BIOLOGICAL AND PATHOLOGICAL ROLES OF
JNK PATHWAYS
In the last 2 decades there has been enormous research interest in
discovering the specific functional roles of JNKs. These studies
established the involvement of JNK signaling pathways in embry-
onic development, neuronal functions, immunity, or in different
pathological states, such as insulin resistance, oncogenic transfor-
mation, and excitotoxicity. In the following section, we briefly
review this large body of research to highlight the breadth of bio-
logical and pathological actions of JNKs.
JNK Involvement in Embryonic Development
The JNKpathway has attracted considerable interest as a target for
gene knockout studies in mice to probe the developmental roles
played by the JNKs. While single-JNK knockout mice, JNK1/,
JNK2/, or JNK3/, are viable, as are double-knockout
JNK2/ JNK3/mice; JNK1/ JNK2/mice die early in em-
bryogenesis (embryonic day 11.5 [E11.5]) (for a detailed sum-
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mary of cellular and behavioral phenotypes of JNK knockout an-
imal models, see reference 2). These multiple knockout mice do
not undergo neural tube closure, and they also display exenceph-
aly (179). The latter severe developmental defect, in which the
brain extrudes outside the skull, is suggested to be a consequence
of deregulated apoptosis (178). However, JNKs do not only con-
tribute to apoptosis regulation, and neural tube closure is a mor-
phogenetic process that also involves the coordinated regulation
of cell migration and cell proliferation. JNKs play a crucial role in
cellmotility and in the developmentalmorphogenesis of epithelial
organs (380–384). In the developing central nervous system, JNKs
are activated by various guidance cues, including netrins and
semaphorins, and JNK activity is required for correct axon trajec-
tories (180, 385, 386). In linewith this, the genetic deletion of JIP3,
an important target and regulator of JNK and its upstream ki-
nases, causes axon guidance defects (387).
Studies onMKK4/ andMKK7/mice have highlighted the
nonredundant roles of these JNK-activating MAP2Ks (reviewed
in references 62 and 388). Indeed, in vivo RNA interference
(RNAi) screens have identified MKK4 as a key regulator of liver
regeneration (389), whereas studies in MKK7/ mice have re-
vealed the critical need forMKK7 in axon elongation in the devel-
oping cerebral cortex (390). The compound disruption of both
the MKK4 and MKK7 genes results in severe growth retardation
and embryonic lethality (E9.5). It is striking that genetic deletion
of single JNK substrates may also phenocopy JNK1/ JNK2/
mice, as observed for mice lacking the actin regulatory protein
MARCKS-like protein 1 (266). While MARCKS-like protein 1
gene deletion causes neural tube defects (391), knockout mice for
c-Jun or ATF2 live longer but die of heart failure or respiratory
failure, respectively (392, 393).
JNK also plays a prominent role in Wnt signaling, with impli-
cations for the regulation of cell polarity (394). One of the three
main branches of the Wnt pathway, the so-called planar cell po-
larity pathway (the PCP pathway), involves recruitment of Rho-
GEF proteins (e.g., Daam1) and activation of Rho family small
GTPases (most notably, Rac1). In turn, the GTP-bound Rac1 ac-
tivates the JNK pathway to generate polarity and drive morpho-
genesis of several organs (395). The extent of PCP pathway acti-
vation depends on the exact nature of the receptor complex:
severalWnt ligands are known that preferentially activate the PCP
pathway and increase JNK activity. Notable examples include
Wnt-11, which is indispensable in heart formation and in renal
epithelial cells, and Wnt-7b, which drives maturation and den-
dritic arborization of hippocampal neurons (395–397). Cross talk
of JNKwith two other developmentally important signaling path-
ways (Hedgehog and Hippo) has also been suggested. Gli is an
important terminal regulator of Hedgehog signaling, and its JNK-
mediated phosphorylation suggests that a direct connection be-
tween MAPK and Hedgehog signaling may occur at the level of
these key regulators (69). Recently, JNK-mediated inhibition of
Hippo signaling was described as a mechanism allowing mechan-
ical strain to influence cell proliferation (286). Taken together,
these studies highlight the multiple actions of JNK signaling in
important cellular events underlying embryonic development.
Neuronal Functions of JNKs
In addition to their roles in embryonic development in brainmor-
phogenesis and neuronal pathfinding, JNKs also affect many neu-
ronal functions in adults. In adults, the brain is the site of highest
JNK expression, and all single-JNK knockout mice have CNS de-
fects to a variable degree (reviewed in reference 2). Since normal
JNK activity is implicated in neuronal development and regener-
ation but overactivation of JNK can induce apoptosis of neurons,
inhibitors of JNKs or their upstream regulators have been pro-
posed as desirable neuroprotective agents (398–400). These ob-
servations highlight JNKs as targets for pharmaceutical interven-
tion to ameliorate stroke and epilepsy, Alzheimer’s disease,
Parkinson’s disease, and Huntington’s disease (reviewed in refer-
ence 2). JNKsmay contribute to the earliest phases of Alzheimer’s
disease (AD); the Tau protein is a well-established substrate of
JNK, and the phosphorylation of Tau might occur at the earliest
stages of synaptic dysfunction and microtubule disassembly, thus
preceding cognitive deficits in ADmodels (265). The inhibition of
JNK activity (causing microtubule disassembly, Tau release,
and/or aggregation)may thus represent one option to prevent the
formation of neurofibrillary tangles and so should be further
tested for its efficacy as a treatment modality.
JNK has also emerged as a central mediator of excitotoxic dam-
age in the adult nervous system. Excitotoxic insults can induce
JNK activation, which leads to neuronal death and contributes to
many neurological conditions, such as cerebral ischemia and neu-
rodegenerative disorders (401, 402). JNK3/ mice are resistant
to kainite-induced seizures (403). Conversely, the pharmacologi-
cal inhibition of JNK protects neurons from N-nitrosyldimethyl-
amine (NMDA)-induced excitotoxicity in vitro and from cerebral
ischemia in animal models (402, 404). Most studies have high-
lighted the involvement of JNK3 in triggering neuronal death, but
other JNK isoforms likely also contribute. For example, presynap-
tic JNK2has been implicated in the regulation of glutamate release
downstreamofNMDA receptor activation (405).However, only a
simultaneous knockdown of JNK1, -2, and -3 was sufficient to
confer neuroprotection, indicating that a single form of JNK is
sufficient to produce a dominant apoptotic signal (406). Further-
more, the inhibition of JNK activity in the nucleus, rather than
blocking specific JNK isoforms globally, protected cells from un-
dergoing apoptosis (406). These results further emphasize the
critical nature of JNK localization in exerting its downstream bio-
logical effects. More recent studies have demonstrated the neuro-
protective efficacy of a peptide targetingMKK7 (407), again high-
lighting that blocking JNK activation can provide an important
strategy in the protection of neurons.
Although JNKs are best known as mediators of neuronal
degeneration after stress and injury, they may be important
also for neural development and survival. JNKs are implicated
in axonal regeneration of adult neurons, as their specific inhi-
bition in vitro reduces neuritogenesis (408). Similarly, JNK in-
hibition slowed nerve regeneration in a sciatic nerve transec-
tion-regeneration model (409). Moreover, distinct roles for
different JNK isoforms were suggested in neurite initiation and
elongation during axonal regeneration (410). Mutations dis-
rupting the JNK3 gene have recently been identified in patients
with hereditary intellectual disability (411), and so these stud-
ies support the roles for JNKs in maintenance of neuronal pop-
ulations for normal development and in the response to injury.
The mechanisms underlying these developmental roles require
further evaluation, but the interaction of JNK1 with neuronal
RNA transport granule proteins (412) will provide exciting
new avenues for exploration.
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JNK in Apoptosis and Cancer
JNKs are involved in the extrinsic apoptotic pathway initiated by
death receptors as well as in the intrinsic pathway initiated at the
mitochondrial level. In response to both extrinsic and intrinsic
apoptotic stimuli, JNKs play an essential role through their inter-
actions that modulate the activities of diverse pro- and antiapop-
totic proteins (reviewed in reference 279). JNK activation is criti-
cal for TNF--stimulated AP-1-dependent gene expression (413)
and has a dual role in the TNF--stimulated death of fibroblasts
by not only suppressing TNF--stimulated apoptosis but also po-
tentiating TNF--stimulated necrosis (414). Moreover, JNKs
negatively regulate the autocrine expression of TGF-1 in fibro-
blasts (414). This allows for complex, indirect effects on survival
and cell growth through the TGF- pathway (reviewed in refer-
ence 415).
Apoptotic cell death is an important process for tumor suppres-
sion, and JNK activation could be expected to be important as a
negative regulator of cancer. However, depending on the cell type
and lineage studied, JNK signal transduction pathways have been
implicated not only in apoptosis but also in cell survival. Accord-
ingly, JNKs have also been implicated in the malignant transfor-
mation and tumorigenesis of cells (reviewed in reference 416). In
transformed B lymphoblasts, JNK1 signals cell survival, as its ge-
netic disruption in mice causes defective transformation of pre-B
cells by BCR-ABL (417). Moreover, JNKs play a key role in Ras-
induced tumorigenesis, for example, in lung tumor development
caused by mutational activation of the endogenous KRas gene
(278). Thus, these studies of the fundamental biological processes
highlight that JNKs can play a balancing role in the regulation of
apoptosis and tumorigenesis.
The kinase domain-encoding portions for MKK4 (MAP2K4)
and to a lesser extent the MKK7 (MAP2K7) genes appear to har-
bor a high number of missense and nonsense mutations (418).
The upstream-actingMEKK1 (MAP3K1) gene (419) was found to
be often mutated in breast cancer, and 12% of luminal A tumors
contained inactivating mutations in MAP3K1 and MAP2K4
(420). Interestingly, MKK4 mutants harboring cancer-associated
somatic mutations had lower enzymatic activity and also caused
anchorage-independent cell growth (421). In summary, large-
scale tumor genome sequencing studies further reinforce the tu-
mor-suppressive role of JNK pathways in certain tissues (419).
JNK Actions in Insulin Resistance and Diabetes
Maintenance of insulin signaling is critical for metabolic homeo-
stasis, with its failure in the form of insulin resistance being a
hallmark of type 2 diabetes. Feeding mice a high-fat diet causes
activation of JNK1 in insulin-responsive peripheral tissues, in-
cluding fat, muscle, and liver, and ultimately leads to insulin re-
sistance in these tissues (181). JNKs are among the key kinases
activated by cytokines TNF-, interleukin-6, and resistin, which
are produced by the adipocytes of obese individuals (337). In these
pathways, JNK1 and JNK2 act in close concert with members of
the IKK family to inhibit insulin signaling through their effectors,
including the insulin receptor substrates IRS1 and IRS2 (422).
JNK1 knockout prevents both diet-induced obesity and insulin
resistance. JNK1/mice, but not wild-type or JNK2/mice, are
resistant to obesity-induced insulin resistance (336). Nonetheless,
JNK2 is also involved in metabolic regulation, but its contribu-
tions are not obvious in the presence of functional JNK1 signaling
(187). Genetic or pharmacological inhibition studies have dem-
onstrated that the chronic activation of JNK1 in obesity may be a
direct cause of insulin resistance (reviewed in reference 423). The
numerous studies using germ line or tissue-specific genetic abla-
tion of JNKs established JNK1 as a potential pharmacological tar-
get for the development of drugs that could be used to counteract
insulin resistance. These observations spurred an intense, but
short-lived, interest in developing JNK inhibitors for therapeutic
agents in type II diabetes (181), but a major portion of the protec-
tive effect seen in JNK1/ mice can stem from dysregulation of
the central nervous system. In the last 10 years, the picture has
becomemore detailed, and JNK1 (and even JNK2)may also play a
role in peripheral insulin resistance: JNK-dependent insulin resis-
tance involves immune cells (424) and skeletal muscle cells to
some extent (423). The presence of JNK in macrophages appears
to be required for the establishment of obesity-induced insulin
resistance and inflammation (424). JNK1 in adipose tissue or in
the muscle regulates insulin resistance, and JNK1 deficiency in
these tissues promotes insulin sensitivity (423, 425). In contrast,
hepatocyte-specific JNK1 deficiency promotes insulin resistance
(423, 426). Interestingly, the phenotype of these lattermice is sim-
ilar to that of IRS1 Ser307Ala substitution in vivo (427). JNK1-
mediated insulin resistance was initially considered mainly medi-
ated by the insulin receptor adapter protein IRS1, phosphorylated
on Ser312 (Ser307 in mice), which disrupts the interaction of the
IRS1 phosphotyrosine-binding (PTB) domain with the tyrosine-
phosphorylated receptor (428). However, analysis of mutant,
knock-in mice demonstrated that the Ser312 site of IRS1 is not
essential for the development of insulin resistance (427). While
the influence of other phosphorylation sites in IRS1 and IRS2
cannot be excluded, most deleterious defects and the origin of
insulin resistance are suggested to occur independently of IRS1
(429). IRS proteins are not the only targets of the JNK pathway:
the insulin secretion-regulating protein MADD and the insulin
sensitivity-influencing PPAR coactivator PGC1 have also been
implicated to be novel JNK targets (80). The role of MADD poly-
morphisms in type II diabetes susceptibility is strongly supported
by genome-wide association studies and mouse models, while
PPAR agonist “glitazones” are among the most widely used an-
tidiabetic agents (422, 430).
Additionally, since cell death in type I diabetes also involves
JNK hyperactivation in pancreatic -cells (causing their death),
various JNK inhibitors have also been studied for the latter indi-
cation (431). However, -cells also express JNK3, and this may
have protective roles, unlike those prodeath roles described for
JNK1 or JNK2 (432). Thus, approaches targeting the JNKs as pos-
sible therapeutic strategies will need to consider both tissue- and
isoform-specific differences.
JNK in Immunity
JNKs play evolutionarily conserved roles in immunity: antibacte-
rial, antiviral, or antiparasitic responses depend on JNK, even in
insects (92, 433). JNKs can be strongly activated in multiple cell
types by lipopolysaccharides (LPS) or inflammatory cytokines
such as TNF- and interleukin-1. Although JNKs, particularly
JNK2, influence T cell functions and Th1/Th2 polarization, they
are nonessential for T cell proliferation and for many aspects of
adaptive immunity (434). JNK1/ or JNK2/ mice have nor-
mal lymphocytes, and JNK activity is not required for all forms of
thymocyte apoptosis (435). Nonetheless, both JNK1 and JNK2
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respond to T cell activators (436) and are required for the induc-
tion of T cell cytokines (182, 437). In addition, JNKs have a stage-
specific role in T cell proliferation and apoptosis; while c-Jun is a
target of both JNKs in thymocytes, it does not seem to be an
important target in peripheral T cells, where both JNK isozymes
contribute to the induction of NF-AT rather than AP-1 activity
(435, 438).
It is well-established that viral infection can result in stimula-
tion of c-Jun–ATF2 via JNK activation; JNK2-deficient cells ex-
hibit a defect in induction of type I interferons in response to viral
infection or double-stranded RNA that allows more robust viral
infection (439). More recent studies have indicated that the JNK
pathways mainly control processes of innate immunity (reviewed
in reference 440). The innate immune response provides the first
line of defense following infection, using a limited number of
germ line-encoded pattern recognition receptors, such as the Toll
or NOD receptors, which recognize invariant microbial compo-
nents, termed pathogen-associated molecular patterns. All of
these receptors activate MAPK and nuclear factor-B (NF-B)
pathways in innate immune cells such as macrophages and den-
dritic cells. During an inflammatory response, NF-B activation
antagonizes apoptosis induced by TNF-. The prosurvival NF-B
activity suppresses proapoptotic JNK signaling, and this is crucial
for numerous physiological processes, such as the response of the
liver to injury and the survival of cells during an inflammatory
reaction, as well as for chronic inflammatory diseases (reviewed in
reference 441). For example, JNK was essential for hepatitis by
being critically required for TNF- expression in hematopoietic
cells, including resident inflammatory cells in the liver (e.g.,
Kupffer cells, which are specialized macrophages located in the
liver, and natural killer T cells) (442), rather than being required
for TNF--stimulated cell death during the development of the
disease. These observations support the notion that JNK can act as
a genuine immune modulator, not merely an apoptosis-inducing
effector.
MICROBIAL PATHOGENS AFFECTING JNK SIGNALING
In addition to inducing an inflammatory response, pathogens
themselves can also modify JNK signaling events. Since JNK is a
key component of innate immunity pathways of many animals,
this is not surprising: many bacteria, viruses, and eukaryotic par-
asites directly “tamper with” the JNK pathway in order to evade,
suppress, or modify immune responses to their advantage (440,
443, 444). Enzymes produced by pathogenic bacteria and injected
into the host cells, in most cases by a type III secretion system, are
among the best examples (reviewed in references 445 and 446).
These can impact different levels in the JNK signaling pathway,
and various catalytic mechanisms have been described.
The YopJ enzyme of Yersinia pestis was one of the first path-
way-subverting enzymes identified; its use of acetyl-coenzyme A
(CoA) as a substrate in an acetyltransferase-mediated modifica-
tion of critical residues in MAP2K activation loops thereby
blocked their phosphorylation and thus activation by MAP3Ks
(447). While YopJ is an acetyltransferase and its recognition of
MAP2Ks has been mapped (448), it is also structurally related to
eukaryotic cysteine peptidases involved in deubiquitinylation and
deSUMOylation. Some experiments have suggested these activi-
ties for the YopJ family of enzymes (449). Unlike YopJ, which also
targets the NF-B pathway, the AvrA enzyme from Salmonella
enterica serovar Typhimurium is more selective for JNK pathway
inhibition. AvrA was found to directly acetylate the activation
loop of MKK7, rendering it permanently inactive, unable to be
phosphorylated (450). Other bacterial acetyltransferases work by
different mechanisms: the VopA acetyltransferase of Vibrio para-
haemolyticus targets a catalytic site lysine of different MAP2K en-
zymes (including MKK6, but others as well), disrupting ATP co-
ordination (451). VopA thus efficiently shuts down both the JNK
and p38 pathways and suppresses host cytokine production. In-
stead of targeting kinases, the Eis acetyltransferase fromMycobac-
terium tuberculosis modifies the MAPK phosphatase MKP7 (also
known as DUSP16) to produce a hyperactive phosphatase that
suppresses both JNK and p38 activity (452). Thus, these acetyl-
transferases act to suppress JNK signaling via targeting different
pathway components, not just the JNKs themselves.
Bacterial proteases can elicit similarly insidious effects. The
NleD protease produced by enteropathogenic Escherichia coli
(EPEC) strains cleaves JNK at its activation loop, resulting in JNK
degradation and immune suppression (453). The lethal factor
(LF) of Bacillus anthracis exerts its effects by a more complex way:
the catalytic site of this protease recognizes substrates with a con-
sensus similar to many MAPK docking motifs found in the host
and is known to cleave the N-terminal docking motifs from
MAP2Ks (454). The truncated MAP2Ks are unable to propagate
ERK1/2, JNK, and p38 signaling, and they may even act as domi-
nant-negative inhibitors at theMAP3K level of theseMAPK path-
ways. The G63 protease produced by the eukaryotic intracellular
parasite Leishmania major cleaves multiple substrates within host
cells, including the adaptor protein Tab1 (455). Without this crit-
ical scaffolding component acting at theMAP3K level, the TNF-,
Toll, and NOD receptors are unable to recruit the TAK1 kinase,
which is necessary for both JNK and p38 pathway activation.
Some pathogen-derived enzymes act through different, per-
haps more exotic mechanisms. The OspF enzyme of Shigella flex-
neri, originally believed to be a phosphatase, is aMAPK-phospho-
threonine-lyase (456). After removal of a phosphate from the
activation loop of MAPKs, the lyase leaves no hydroxyl group
behind,making rephosphorylation and henceMAPK reactivation
impossible (457). Although OspF displays a much higher activity
on ERK2 or p38 than on JNKs, the related Spvc enzyme from
Salmonella Typhimurium targets phospho-JNK and phospho-
ERK2 (458). Interestingly, even plant pathogens use similar en-
zymes (such as HopAI1 from Pseudomonas syringae) to interfere
with MAPK-driven innate immunity responses of the host (459).
Members of the Theileria genus of intracellular parasites (respon-
sible for human as well as animal diseases) are unique among
eukaryotes in that they can induce oncogenic transformation of
infected cells. In the case of Theileria annulata, oncogenic trans-
formation is elicited via secretion of the protein TaPIN1 into the
host cells. This enzyme is related to themammalian Pin1 peptidyl-
prolyl cis-trans isomerase and acts by disabling the host FBW7
ubiquitin ligase system, thereby allowing c-Jun overproduction
(460).
While suppression of JNK activity is advantageous to many
pathogens, there are some pathogens that intentionally activate
the JNK pathway. The latent membrane protein 1 (LMP1) en-
coded by Epstein-Barr virus is absolutely necessary to promote
survival of infected B lymphocytes. LMP1 is a multipass mem-
brane protein with an N-terminal oligomerization domain and a
C-terminal cytoplasmic segment. The latter contains two critical
linear motifs, one for the recruitment of TRAF6 and another for
Zeke et al.
820 mmbr.asm.org September 2016 Volume 80 Number 3Microbiology and Molecular Biology Reviews
 o
n
 Septem
ber 27, 2016 by SEM
M
ELW
EIS UNIV
http://m
m
br.asm
.org/
D
ow
nloaded from
 
the interaction with TRADD that is necessary to recruit TRAF2
(461). Thus, LMP1 can mimic activated TNF--like receptors; it
interferes with the B cell proliferation response by turning on
TRAFs and increasing JNK and NF-B activation. In infected B
cells, JNK pathway activation can promote survival and stop
apoptosis when coactivated with NF-B (462). Furthermore, sev-
eral other viruses also intentionally activate the JNK pathway as a
mechanism in the induction of cell cycle arrest or even apoptosis.
This can help human immunodeficiency virus (HIV) tomodulate
T cell functions, enhance varicella-zoster virus (VZV) replication
more efficiently, and promote virion release for coxsackievirus
group B3 (463–465). However, themolecular-level details of these
latter interactions await characterization.
CONCLUSIONS
JNK functions in specialized tissues can greatly differ. However,
one overarching problem remains unresolved even after decades
of research: how do JNK pathways “decide” between responses
that promote survival and those ultimately leading to cell death?
Experimental findings suggestmultiple possible answers to this
conundrum. That overexpression or overactivation of JNK1 al-
most invariably results in cell death inmost cell types suggests that
the level of JNK pathway activation must be important. In this
“thresholdmodel,” low levels of JNK activity drive essentially pro-
survival responses, while overactivation causes switching to cell
cycle arrest and sensitization to apoptotic stimuli. The observation
that some JNK pathways contain positive feedback loops is signif-
icant in this regard. Other experiments have suggested the impor-
tance of spatiotemporal separation of JNK activity. In this “local-
ization model,” cytoplasmic JNK activity is part of normal
developmental procedures, while the actions of activated JNKs in
the nucleus trigger events culminating apoptosis. These twomod-
els do not necessarily contradict each other. In the context of neu-
roblasts, highly localized JNK activity is detected at the axonal
growth cone tips (122) and is required to guide the axon to its
destination as part of normal physiology. On the other hand, an
increase of JNK activity around the nucleus would prevent growth
and, if sustained, drive the outcome toward cell death.
The subcellular localizations of JNKs and their upstream reg-
ulators will continue to add further complexities to our under-
standing of JNK signal transduction pathways. Thus, apart from
the well-accepted roles for JNKs in their phosphorylation of nu-
clear substrates, their roles in regulating cytoplasmic targets and
mitochondrial proteins are emerging. In addition, studies on up-
stream kinases have begun to reveal the importance of their local-
ization in influencing JNK pathway actions (466, 467). More in-
depth analyses of compartmentalization of JNK signaling will
require greater development and use of biosensors capable of re-
porting JNK activities in different subcellular locations. This has
been shown with a Jun-based fluorescence resonance energy
transfer (FRET) biosensor, which reported JNK activity and its
subsequent targeting to different intracellular locations (468).
Furthermore, such cell-based assays have andwill allow the exam-
ination of system-level behavior of the JNK cascade and have been
instrumental in revealing the all-or-none behavior of stress-acti-
vated JNK signaling (468). Clearly, a more thorough consider-
ation of the time course of JNK activation will also be critical in
this context (469).
Lastly, greater efforts must be directed toward understanding
the complexities of the JNK signaling events at a theoretical level if
we are to integrate the information onupstream regulatory events,
scaffolds, and substrates into a working model of JNK actions. Of
interest are recently developed models of JNK activation that in-
dicate that the double phosphorylation events observed at numer-
ous upstream points in the MAPK pathways, although not as ef-
ficient as monophosphorylation events, may have evolved
together with scaffold proteins to drive both tighter control and
higher specificity in signaling events (470). After 20 years of
intense interest and research on JNKs, we propose that the baffling
complexity of JNK signaling may be best tackled by the explora-
tion of the complex protein-protein interactions of the JNKs with
their regulators and substrates. These studies will provide new
mechanistic insights into how JNKs can integrate their protein
kinase activity into higher-order protein network activities at the
cellular or organism level. We anticipate that the next decade will
bring amore quantitative, system-level understanding of JNK sig-
naling.
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